{"study_id": 101775, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to identify a subtype of schizophrenia based on carbonyl stress and explore the potential of using carbonyl stress markers (pentosidine and pyridoxal) as biomarkers for personalized treatment.", "results_summary": "The study found that a subpopulation of schizophrenia patients exhibited idiopathic carbonyl stress, leading to plasma pentosidine accumulation and serum pyridoxal depletion. These markers may help distinguish a specific subgroup of schizophrenics for more effective, personalized treatment.", "population_specificity": "Subpopulation of schizophrenia patients with carbonyl stress.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:51.569634+00:00"}
{"study_id": 101777, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of SGK1 in platelet function and its potential link to clinical conditions influenced by Advanced Glycation End Products (AGEs).", "results_summary": "The study found that SGK1 enhances Ca(2+) signaling in platelets, which may contribute to altered platelet function in conditions like diabetes and chronic renal failure, where AGEs are elevated. However, the direct effects of AGEs on platelet function were not explicitly detailed.", "population_specificity": "Megakaryocytes and circulating platelets (in vitro or animal model implied, not explicitly stated).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:51.792291+00:00"}
{"study_id": 101771, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effect of vitamin D supplementation on glycaemic control and quality of life in patients with type 2 diabetes mellitus, including the measurement of advanced glycation end products.", "results_summary": "The abstract does not provide specific results regarding advanced glycation end products, as the study is described as ongoing or not yet concluded.", "population_specificity": "Patients with type 2 diabetes mellitus treated with lifestyle advice, metformin, or sulphonylurea-derivatives in the Netherlands.", "effective_dosage": "50,000 IU Vitamin D3 at monthly intervals.", "study_duration": "Six months.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:51.915926+00:00"}
{"study_id": 101774, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize advances in understanding how dietary polyphenols and polyphenol-rich diets influence the prevention and management of type 2 diabetes, including their effects on advanced glycation end products (AGEs).", "results_summary": "The study found that dietary polyphenols, particularly anthocyanins, may help prevent type 2 diabetes by protecting pancreatic \u03b2-cells, reducing inflammation and oxidative stress, inhibiting starch-digesting enzymes, and decreasing AGE formation. However, the impact of type 2 diabetes on the pharmacokinetics and bioactivity of polyphenols remains poorly understood.", "population_specificity": "General discussion on dietary polyphenols and type 2 diabetes, no specific population mentioned.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:52.983975+00:00"}
{"study_id": 101773, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether ergocalciferol (vitamin D2) improves microcirculatory endothelial function and reduces tissue advanced glycation end products in patients with chronic kidney disease and vitamin D deficiency.", "results_summary": "Ergocalciferol significantly improved endothelium-dependent microcirculatory vasodilation and reduced tissue advanced glycation end products, but did not affect sublingual microcirculatory parameters or macrovascular stiffness beyond pulse pressure.", "population_specificity": "38 patients with non-diabetic chronic kidney disease (stage 3-4) and vitamin D deficiency (<16 ng/dl).", "effective_dosage": "50,000 IU weekly for one month, then 50,000 IU monthly.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:53.353923+00:00"}
{"study_id": 101772, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 80, "study_goal": "The researchers aimed to assess whether remote ischemic conditioning (RIC) could reduce ischemia-reperfusion injury and improve outcomes in lung transplantation, indirectly examining the role of advanced glycation end products (AGEs) in this process.", "results_summary": "The study found no significant improvement in P/F ratios or primary graft dysfunction (PGD) with RIC, though subgroup analysis suggested potential benefits for patients with restrictive lung disease. AGE-related markers (e.g., endogenous secretory receptor for AGEs) peaked post-reperfusion but were likely linked to donor organ quality rather than RIC.", "population_specificity": "60 patients undergoing bilateral sequential lung transplantation.", "effective_dosage": "Not specified (RIC involved 3 cycles of lower limb ischemic conditioning).", "study_duration": "Intervention occurred pre-reperfusion; follow-up included 24-hour post-transplant assessment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:53.485156+00:00"}
{"study_id": 101781, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to understand how regular aerobic exercise affects age-associated arterial dysfunction, particularly its role in reducing oxidative stress and advanced glycation end-products (AGEs).", "results_summary": "The study found that aerobic exercise reduces arterial stiffness and preserves endothelial function by decreasing oxidative stress, collagen fibrosis, and AGE-related structural protein cross-linking. It also enhances nitric oxide bioavailability and suppresses chronic vascular inflammation.", "population_specificity": "Previously sedentary late middle-aged and older adults.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:33:59.576896+00:00"}
{"study_id": 101778, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review the role of HMGB1 in the pathogenesis of acute and chronic sterile inflammatory conditions, including its interaction with the receptor for advanced glycation end products (RAGE).", "results_summary": "The abstract highlights that HMGB1 interacts with RAGE and other receptors, contributing to disease development and progression. Targeting HMGB1 has shown promise in reducing inflammation in sterile inflammatory disease models.", "population_specificity": "Not specified (review article, not a clinical study)", "effective_dosage": "Not available", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:00.909476+00:00"}
{"study_id": 101779, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of vitamin D in ovarian physiology, including its effects on genes related to steroidogenesis, follicular development, and ovarian reserve, as well as its impact on PCOS and ART outcomes.", "results_summary": "Vitamin D supplementation in VD-deficient women with PCOS lowered abnormally elevated serum AMH levels and increased antiinflammatory sRAGE serum levels, suggesting potential benefits for folliculogenesis. However, data on VD supplementation's impact on IVF pregnancy rates were lacking.", "population_specificity": "Human, animal, and cell culture models, with a focus on women with PCOS and those undergoing ART.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:01.017233+00:00"}
{"study_id": 101782, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) and their receptor RAGE in chronic immune imbalance in diabetic patients, and explore noninvasive measurement methods and therapeutic interventions.", "results_summary": "The study found that AGEs and RAGE contribute to chronic immune imbalance in diabetic patients, leading to ineffective inflammatory responses in diabetic wounds. A noninvasive skin autofluorescence method was identified as a promising tool for AGEs assessment, and anti-AGE therapies showed potential in reducing AGE-related damage.", "population_specificity": "Diabetic patients, particularly those with chronic subclinical inflammation and complications like neuropathy and atherosclerosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:01.298526+00:00"}
{"study_id": 101784, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 60, "study_goal": "The researchers aimed to explore the mechanisms by which organophosphorus pesticides (OPs) contribute to insulin resistance and type 2 diabetes, including the role of advanced glycation end products.", "results_summary": "The study suggests that OPs impair glucose homeostasis, promote insulin resistance, and increase the risk of type 2 diabetes through mechanisms involving advanced glycation end products, lipid metabolite accumulation, inflammation, and oxidative stress. These processes negatively affect insulin signaling via serine kinases.", "population_specificity": "Not specified (general discussion of experimental and clinical data).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:01.432421+00:00"}
{"study_id": 101776, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of post-translational modifications (PTMs), including advanced glycation end products, in myocardial ischemia/reperfusion injury and their impact on cardioprotection, particularly in the context of type 2 diabetes mellitus.", "results_summary": "The study found that advanced glycation end products, resulting from hyperglycemia in type 2 diabetes, contribute to aberrant PTMs that may impair cardioprotective mechanisms, such as post-conditioning, in the diabetic heart. Key proteins involved in calcium regulation were differentially modified by PTMs, influencing functional outcomes in physiological and pathophysiological states.", "population_specificity": "The study focuses on myocardial ischemia/reperfusion injury, particularly in the context of type 2 diabetes mellitus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:02.853019+00:00"}
{"study_id": 101785, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in diabetic vascular complications, particularly their contribution to oxidative stress and PKC activation.", "results_summary": "The study found that AGEs, along with other factors like ROS and hyperglycemia, contribute to PKC activation, leading to endothelial dysfunction, impaired vasodilation, and increased vascular contractility in diabetes. PKC activation also elevates VEGF expression and NADPH oxidase activity, exacerbating oxidative stress.", "population_specificity": "Individuals with diabetes mellitus (DM) and associated vascular complications.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.171582+00:00"}
{"study_id": 101786, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to identify modifiable risk factors, including Advanced Glycation End Products, that influence the risk of diabetic kidney disease (DKD).", "results_summary": "The study identified Advanced Glycation End Products as a modifiable risk factor for DKD, suggesting that managing such factors may improve prognosis in diabetic patients. However, specific efficacy data or clinical outcomes related to Advanced Glycation End Products were not detailed.", "population_specificity": "Diabetic patients at risk of DKD.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.231407+00:00"}
{"study_id": 101788, "supplement_id": 857, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of a high-AGE diet versus a low-AGE diet on endothelial function, circulating AGEs, inflammatory mediators, and AGE receptors in healthy adults.", "results_summary": "The study found that a low-AGE diet reduced serum and urine CML levels but had no significant impact on endothelial function or inflammatory mediators. A high-AGE diet showed no significant changes in CML levels or any measured health outcomes.", "population_specificity": "24 healthy adults aged 50-69 years.", "effective_dosage": "Not specified (diets prepared at high or mild temperatures).", "study_duration": "6 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.341832+00:00"}
{"study_id": 101787, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to explore potential mechanisms, including Advanced Glycation End Products (AGEs), by which diabetes mellitus may contribute to cognitive impairment and dementia.", "results_summary": "The abstract suggests that AGEs may be one of several factors involved in cognitive impairment in diabetes, but it does not provide specific findings on AGEs' effects. The focus is on broader mechanisms and the need for multimodal therapies.", "population_specificity": "Patients with diabetes mellitus (DM) at risk of cognitive impairment, dementia, or stroke.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.547836+00:00"}
{"study_id": 101789, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the link between soluble receptor for advanced glycation end-products (sRAGE) and endothelial function during acute exacerbations of COPD and after clinical recovery.", "results_summary": "The study found that sRAGE levels and endothelial function were significantly impaired during acute exacerbations of COPD but improved after clinical recovery, with a positive association between sRAGE and endothelial function.", "population_specificity": "Patients with moderate to severe COPD admitted to the hospital due to acute exacerbations, without overt cardiovascular comorbidities (27% female).", "effective_dosage": "Not specified", "study_duration": "Measurements were taken during hospitalization and after confirmed clinical stability (exact duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:09.993000+00:00"}
{"study_id": 101780, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in obesity-associated cardiac fibrosis and their potential contribution to heart failure and postinfarction remodeling.", "results_summary": "The abstract suggests that AGEs are implicated in the regulation of fibrotic responses in obesity, alongside other molecular processes like oxidative stress and leptin-mediated actions, but does not provide specific outcomes or data on AGEs' effects.", "population_specificity": "Animal models and human patients with obesity and metabolic dysfunction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:10.504661+00:00"}
{"study_id": 101790, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of pioglitazone and glimepiride on the RAGE system in type 2 diabetic patients.", "results_summary": "Pioglitazone significantly increased plasma esRAGE and sRAGE levels while reducing RAGE expression in mononuclear cells compared to glimepiride, independent of glucose or insulin resistance changes.", "population_specificity": "Type 2 diabetic patients aged 20-80 years with hemoglobin A1c levels of 6.4-10.3%.", "effective_dosage": "Pioglitazone (15-30 mg/day), glimepiride (0.5-4 mg/day).", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:11.390489+00:00"}
{"study_id": 101791, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to explore how nutrients and caloric intake, including advanced glycation end products (AGE), influence KRAS-driven pancreatic ductal carcinogenesis through metabolic stress mediators.", "results_summary": "The abstract suggests that AGE, along with other metabolic mediators like RAGE, HMGB1, and glutamine pathways, may play a role in pancreatic cancer metabolism, but no specific findings on AGE's effects are detailed.", "population_specificity": "Not specified (abstract focuses on pancreatic cancer biology broadly).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:18.135043+00:00"}
{"study_id": 101793, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in diabetic vascular complications and identify potential therapeutic targets, including blockade of AGE formation and RAGE activation.", "results_summary": "The study suggests that AGEs and their interaction with RAGE contribute to diabetic vascular complications, alongside other pathways like hyperglycemia and RAAS activation. It highlights the potential of targeting Nox-derived ROS, AGE formation, and RAGE activation as superior strategies to mitigate vascular damage in diabetes.", "population_specificity": "Diabetic patients and individuals at risk for diabetic vascular complications.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:18.799866+00:00"}
{"study_id": 101796, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to understand the role of methylglyoxal and advanced glycation end-products in cardiovascular complications associated with diabetes and explore potential therapeutic targets.", "results_summary": "The study found that methylglyoxal, a precursor to advanced glycation end-products, contributes to endothelial cell damage in diabetes, and the glyoxalase system's failure exacerbates this damage. Targeting methylglyoxal may offer therapeutic potential for preventing cardiovascular complications in diabetes.", "population_specificity": "Individuals with diabetes (specific details not provided).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:19.224692+00:00"}
{"study_id": 101795, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of advanced glycation end products (AGEs) and their receptor RAGE in osteoarthritis (OA) and rheumatoid arthritis (RA), focusing on potential diagnostic markers and therapeutic targets.", "results_summary": "The study found weak correlations between AGEs (such as pentosidine) and joint damage in early-stage OA, identified RAGE as a receptor in synovial tissue, and suggested that RAGE activation may reduce glyoxalase I (Glo1) expression, potentially increasing AGEs in OA and RA.", "population_specificity": "Patients with osteoarthritis (OA) and rheumatoid arthritis (RA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:19.773091+00:00"}
{"study_id": 101794, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to review the role of Advanced Glycation End Products in impairing postischemic revascularization in diabetic patients, particularly in myocardial infarction or critical limb ischemia.", "results_summary": "The study found that Advanced Glycation End Products contribute to impaired angiogenesis in diabetic patients by disrupting proangiogenic pathways and activating antiangiogenic signals, leading to worsened ischemic injury and adverse tissue remodeling. The diabetic environment also impairs the function of bone marrow-derived cells that promote angiogenesis.", "population_specificity": "Patients with diabetes mellitus, particularly those with myocardial infarction or critical limb ischemia.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:20.177565+00:00"}
{"study_id": 101797, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs), particularly those derived from methylglyoxal (MG), in diabetic complications and their potential as biomarkers for predicting diabetic nephropathy progression.", "results_summary": "The study found that specific plasma AGE biomarkers (MG-H1, CEL, and CML) predict fast progression of diabetic nephropathy, supporting MG's role in pathogenesis. Metformin was shown to reduce MG-related AGEs, and lowering post-meal glucose decreased MG and MG-related AGE levels.", "population_specificity": "Individuals with diabetes, particularly those susceptible to diabetic complications.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:20.243666+00:00"}
{"study_id": 101792, "supplement_id": 857, "safety_score": "70", "efficacy_score": 40, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and efficacy of PF-04494700, a RAGE inhibitor, in patients with mild to moderate Alzheimer's disease.", "results_summary": "The high dose (20 mg/d) was associated with adverse events and cognitive decline, while the low dose (5 mg/d) showed a good safety profile and a potential but inconclusive benefit on cognitive decline at 18 months. No differences were observed in other clinical or biomarker measures between the low-dose and placebo groups.", "population_specificity": "Patients with mild to moderate Alzheimer's disease (Mini-Mental State Examination score 14-26).", "effective_dosage": "High dose: 60 mg/day for 6 days, then 20 mg daily; low dose: 15 mg/day for 6 days, then 5 mg daily.", "study_duration": "18 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:20.974447+00:00"}
{"study_id": 101798, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of dicarbonyl overload and AGEs in disrupting ovarian function and fertility, particularly focusing on oocyte susceptibility to methylglyoxal.", "results_summary": "The study found that AGEs contribute to perturbations in the ovarian microenvironment, reducing fertility, and highlighted the glyoxalase system as a protective mechanism against dicarbonyl stress in reproductive-age women and patients with PCOS or diabetes.", "population_specificity": "Reproductive-age women, particularly those with PCOS or diabetes.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:26.509664+00:00"}
{"study_id": 101801, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore novel therapeutic approaches for diabetic kidney disease (DKD), including advanced glycation end products treatments, based on recent advances in understanding DKD pathophysiology.", "results_summary": "The abstract does not provide specific findings on advanced glycation end products treatments but highlights them as a potential novel therapy for DKD alongside other targets like JAK inhibitors and protein kinase C.", "population_specificity": "Individuals with diabetic kidney disease (DKD).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:27.109893+00:00"}
{"study_id": 101800, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effects of enalapril/lercanidipine combination on emerging cardiovascular risk biomarkers, including soluble advanced glycation end products (sRAGE), in hypertensive patients.", "results_summary": "The enalapril/lercanidipine combination increased sRAGE levels more effectively than monotherapies, suggesting a potential benefit in cardiovascular risk stratification. All treatments improved sRAGE levels, with the combination showing the strongest effect.", "population_specificity": "345 hypertensive patients (120 on enalapril, 110 on lercanidipine, 115 on the combination).", "effective_dosage": "Enalapril 20 mg, lercanidipine 10 mg, or enalapril/lercanidipine 20/10 mg fixed combination.", "study_duration": "24 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:29.011085+00:00"}
{"study_id": 101799, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether replacing short-acting insulin with glulisine improves glycemic control and reduces vascular injury markers, including Advanced Glycation End Products (AGEs), in diabetic patients.", "results_summary": "Switching to glulisine significantly reduced HbA1c, AGEs, sRAGE, MCP-1, and urinary albumin excretion, suggesting improved glycemic control and vascular health. The study also noted increased treatment satisfaction with glulisine.", "population_specificity": "59 diabetic patients (49 type 1, 10 type 2; mean age 52.9 \u00b1 13.3 years) with uncontrolled blood glucose (HbA1c > 6.2%).", "effective_dosage": "Multiple daily pre-meal injections of glulisine (exact dosage not specified).", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:29.192947+00:00"}
{"study_id": 101802, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to explore the potential of pyridoxamine and other emerging therapeutic agents in combating diabetic nephropathy by targeting advanced glycation end products.", "results_summary": "The abstract suggests that current evidence is not persuasive for the clinical application of these agents, though they may offer a complementary strategy to RAAS blockade. The authors highlight the need for further research and combination therapies.", "population_specificity": "Individuals with diabetic nephropathy (implied, not explicitly stated).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:29.357376+00:00"}
{"study_id": 101804, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the elimination efficiency of middle-sized uremic solutes, including advanced glycation end-products (AGEs), between conventional high-flux membranes and modified high-cut-off (HCO) membranes.", "results_summary": "The study found that HCO membranes removed high molecular AGEs significantly better than conventional high-flux membranes, though albumin loss was higher with HCO membranes.", "population_specificity": "12 patients undergoing haemodialysis or haemodiafiltration.", "effective_dosage": "Not specified", "study_duration": "Each patient underwent four treatments (two with HCO and two with PF dialyzers).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:30.343989+00:00"}
{"study_id": 101803, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in the induction and progression of diabetic medial artery calcification (MAC).", "results_summary": "The study identified AGEs as one of multiple contributing factors to diabetic MAC, alongside inflammation, oxidative stress, and hyperphosphatemia, but did not isolate or quantify their specific effects. It highlighted the role of osteoblast-like cells and transcription factors in vascular calcification but did not evaluate interventions targeting AGEs.", "population_specificity": "Diabetic individuals with medial artery calcification (MAC).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:30.542749+00:00"}
{"study_id": 101783, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to analyze the roles of HMGB1, including its interaction with the receptor for advanced glycation end products (RAGE), in physiological and pathological conditions, particularly in pediatric diseases.", "results_summary": "The abstract highlights HMGB1's involvement in inflammatory and autoimmune diseases, tumor progression, and neuroinflammation, suggesting its potential as a therapeutic target and diagnostic biomarker. However, specific effects of advanced glycation end products (AGEs) are not detailed.", "population_specificity": "Pediatric diseases (broadly mentioned, no specific demographic details provided).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:34.435825+00:00"}
{"study_id": 101806, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the prognostic value of advanced glycation end products (AGEs) as a risk marker for diabetic kidney disease (DKD) progression.", "results_summary": "The study identified AGEs as an emerging risk marker for progressive kidney function loss in DKD, but noted they currently serve only as risk identifiers rather than confirmed causal factors. Further research is needed to determine if modulating AGEs improves DKD prognosis.", "population_specificity": "Patients with diabetic kidney disease (DKD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:36.469982+00:00"}
{"study_id": 101805, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to summarize the role and significance of the S100 family signaling network, including its interaction with Advanced Glycation End Products (RAGE), in pancreatic cancer progression and metastasis.", "results_summary": "The study found that S100 proteins interact with RAGE, p53, and p21, contributing to extracellular matrix degradation and metastasis in pancreatic cancer. S100A11, S100P, S100A2, S100A6, and S100A4 were identified as significant biomarkers linked to prognosis, drug resistance, and clinical outcomes.", "population_specificity": "Pancreatic cancer patients, particularly those who have undergone surgical resection.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:36.703755+00:00"}
{"study_id": 101807, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of S100A8/A9 (a DAMP linked to RAGE) in cardiovascular disease pathogenesis and its potential as a biomarker and therapeutic target.", "results_summary": "The study found that S100A8/A9 levels correlate with cardiovascular risk factors, atherosclerosis extent, and future coronary events. It promotes inflammation and atherogenesis, suggesting its utility as a biomarker and therapeutic target.", "population_specificity": "Humans (healthy individuals and myocardial infarction survivors) and mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:37.703485+00:00"}
{"study_id": 101811, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the bidirectional relationship between diabetes and periodontitis, including the role of advanced glycation end-products (AGEs) in this interaction.", "results_summary": "The study suggests that AGEs may contribute to periodontitis in diabetic individuals through mechanisms like inflammation and bone uncoupling, but it does not quantify their direct effects.", "population_specificity": "Individuals with diabetes and periodontitis.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:38.643797+00:00"}
{"study_id": 101808, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) and their receptor RAGE in the pathophysiology of rheumatoid arthritis (RA) and identify them as potential therapeutic targets.", "results_summary": "The abstract suggests that AGEs and RAGE play a critical role in RA pathophysiology, highlighting them as potential therapeutic targets alongside other cytokines and signaling pathways. However, specific efficacy data on AGEs are not detailed.", "population_specificity": "Rheumatoid arthritis patients (implied, not explicitly stated).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:38.656845+00:00"}
{"study_id": 101810, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to examine the effects of Alagebrium (an AGE-crosslink breaker) and exercise training on endothelial function, arterial stiffness, and cardiovascular risk in older individuals.", "results_summary": "Exercise training improved physical fitness and reduced lifetime cardiovascular risk but did not affect endothelial function or arterial stiffness. Alagebrium had no independent effect on vascular function and did not enhance the benefits of exercise.", "population_specificity": "48 non-exercising older individuals (mean age 70 \u00b1 4 years) without manifest diseases or medication use.", "effective_dosage": "200 mg/day Alagebrium", "study_duration": "1 year", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:39.196363+00:00"}
{"study_id": 101809, "supplement_id": 857, "safety_score": "70", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of TTP488, an antagonist at the Receptor for Advanced Glycation End products, as a treatment for mild-to-moderate Alzheimer's disease (AD).", "results_summary": "The study found that a 5 mg/day dose of TTP488 showed numerical and nominal significant differences favoring reduced cognitive decline compared to placebo, particularly in patients with mild AD. Higher doses (20 mg/day) were associated with acute, reversible cognitive worsening.", "population_specificity": "Patients with mild-to-moderate Alzheimer's disease.", "effective_dosage": "60 mg for 6 days followed by 20 mg/day; 15 mg for 6 days followed by 5 mg/day.", "study_duration": "18 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:39.212110+00:00"}
{"study_id": 101812, "supplement_id": 857, "safety_score": "20", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the relationship between exogenous advanced glycation end products (AGEs), chronic inflammation, insulin resistance (IR), and type 2 diabetes (T2D), and evaluate dietary AGE restriction as a nonpharmacologic intervention.", "results_summary": "The study found that excessive consumption of AGEs contributes to chronic inflammation, IR, and T2D, and that dietary AGE restriction effectively lowers AGE levels, restores innate defenses, and improves IR.", "population_specificity": "Not specified (general discussion, likely referencing broader populations with IR or T2D).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:42.715931+00:00"}
{"study_id": 101813, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine whether salsalate treatment reduces serum levels of early and advanced glycation end products (AGEs) in people with type 2 diabetes.", "results_summary": "Salsalate lowered early glycation products (HbA1c and furosine) and CML but did not affect other AGEs (CEL, G-(1)H, MG-(1)H). Pentosidine levels increased significantly, suggesting potential oxidative stress or reduced clearance.", "population_specificity": "Adults with type 2 diabetes (118 salsalate-treated, 109 placebo).", "effective_dosage": "3.5 g/day of salsalate.", "study_duration": "48 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.011522+00:00"}
{"study_id": 101814, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review strategies for inhibiting HMGB1-RAGE interaction to modulate inflammatory and tumor-facilitating activity.", "results_summary": "The study found that blocking HMGB1-RAGE signaling is a promising approach for treating chronic inflammatory and autoimmune diseases, with various molecules identified as effective inhibitors, including small molecules, antibodies, and peptides. Encouraging results were noted with HMGB1-targeting compounds.", "population_specificity": "Not specified (review of literature).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.133328+00:00"}
{"study_id": 101815, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of gut dysbiosis and advanced glycation end-products (AGEs) in chronic kidney disease (CKD) development and assess the potential of probiotics to mitigate uremic toxin accumulation.", "results_summary": "The study hypothesizes that gut dysbiosis contributes to systemic uremic toxin loads, including AGEs, and suggests that probiotics may reduce these toxins by promoting healthy ROS production in the gut, offering a potential early treatment for CKD.", "population_specificity": "Patients with chronic kidney disease (CKD), particularly end-stage (type 5).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:45.351632+00:00"}
{"study_id": 101816, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to determine whether advanced glycation end products (AGEs) and their receptors play a role in female reproduction, particularly in polycystic ovary syndrome (PCOS) and infertility.", "results_summary": "The study found that AGEs are intricately linked to granulosa cell dysfunction, adipocyte pathophysiology, obesity, and insulin resistance in PCOS. Additionally, irregular ovarian AGE signaling may contribute to abnormal ovarian histology in PCOS and affect ovarian reserve and assisted reproduction outcomes.", "population_specificity": "Women with PCOS, polycystic ovary animal models, and women without PCOS.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:47.015169+00:00"}
{"study_id": 101817, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to review the mode of action of tasquinimod as a novel oral anti-cancer agent, focusing on its effects on the tumour microenvironment, including its interaction with Advanced Glycation End Products.", "results_summary": "Tasquinimod inhibits tumour growth and metastasis by targeting myeloid-derived suppressor cells and tumour-associated macrophages, modulating local tumour immunity via blocking S100A9 interaction with Advanced Glycation End Products and Toll-like receptor 4. It also exhibits anti-angiogenic effects through histone deacetylase-4 inactivation and reduced hypoxia-inducible factor 1-controlled gene expression.", "population_specificity": "Preclinical studies (in vitro and in vivo) with potential implications for various solid tumours in humans.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:47.759879+00:00"}
{"study_id": 101819, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore the potential benefits of new antidiabetic agents (DPP-4 inhibitors and GLP-1 agonists) on bone health, particularly their role in inhibiting advanced glycation end products and bone resorption.", "results_summary": "The study suggests that DPP-4 inhibitors and GLP-1 agonists may benefit bone health by stimulating osteoblasts, inhibiting advanced glycation end products, and reducing bone resorption, though clinical evidence in humans remains insufficient for definitive conclusions.", "population_specificity": "Patients with Type 2 Diabetes Mellitus (T2D) at risk of osteoporosis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:47.891798+00:00"}
{"study_id": 101818, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the association of plasma biomarkers, including soluble receptor for advanced glycation end products (sRAGE), with acute respiratory distress syndrome (ARDS) diagnosis and mortality.", "results_summary": "Increased levels of soluble receptor for advanced glycation end products (sRAGE) were strongly associated with ARDS diagnosis in at-risk populations (odds ratio 3.5 [1.7-7.2]). The study ranked sRAGE among the top biomarkers for ARDS diagnosis.", "population_specificity": "Patients at risk for or diagnosed with acute respiratory distress syndrome (ARDS).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:47.976882+00:00"}
{"study_id": 101820, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare tissue advanced glycation end products (AGEs) levels in kidney transplant recipients with those in CKD stage 3 and dialysis patients, and to assess the impact of transplantation on AGEs.", "results_summary": "Transplant recipients had significantly lower AGEs levels than dialysis patients but similar levels to CKD stage 3 patients. Transplantation was associated with a reduction in AGEs, potentially contributing to lower cardiovascular risk in transplant recipients.", "population_specificity": "66 kidney transplant recipients, 1,707 CKD stage 3 patients, and 115 dialysis patients.", "effective_dosage": "Not specified", "study_duration": "Mean follow-up of 16 months post-transplantation for a small cohort.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:51.138501+00:00"}
{"study_id": 101821, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 85, "study_goal": "The researchers aimed to determine whether combining exercise with alagebrium (an advanced glycation end product crosslink breaker) would improve left ventricular stiffness in sedentary older humans.", "results_summary": "Alagebrium showed a modest improvement in LV stiffness but had no effect on hemodynamics, LV geometry, or exercise capacity. Exercise alone improved exercise capacity and LV mass but did not significantly impact LV stiffness.", "population_specificity": "Healthy, previously sedentary seniors (67 \u00b1 6 years; 37 female, 20 male).", "effective_dosage": "200 mg/d of alagebrium.", "study_duration": "1 year.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:52.577386+00:00"}
{"study_id": 101822, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to provide an updated overview of mass spectrometry-based procedures for identifying and characterizing glycation/glycoxidation protein targets and their adducts, highlighting current limitations in proteomic approaches.", "results_summary": "The study reviewed proteomic methods for analyzing Advanced Glycation End Products (AGEs), noting their chemical complexity and diversity as challenges. It emphasized the limitations of current techniques compared to other post-translational modification analyses.", "population_specificity": "Not specified (general review of proteomic methods)", "effective_dosage": "Not available", "study_duration": "Not applicable (review article)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:53.071945+00:00"}
{"study_id": 101823, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine the impact of lifestyle factors (physical exercise and feeding regimen) on skin autofluorescence as a marker of advanced glycation end products (AGEs) accumulation in Slovakian and Dutch populations.", "results_summary": "Slovaks generally had lower skin autofluorescence than Dutch Caucasians, except in the 10-19 age group. Regular physical exercise (\u22653 times/week for >30 min/day) was associated with lower AGE levels in adults, and breastfeeding (AGE-poor diet) was linked to lower AGE levels in infants compared to formula feeding (AGE-rich diet).", "population_specificity": "1385 apparently healthy Slovakian subjects (from infants to 77 years old) and Dutch Caucasian reference data.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:54.803367+00:00"}
{"study_id": 101827, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of three ARBs (telmisartan, irbesartan, candesartan) in inhibiting the HMGB1-RAGE axis for stroke prevention and acute treatment.", "results_summary": "The study found that ARBs inhibiting the HMGB1/RAGE axis may offer a novel option for stroke prevention and acute treatment, but additional clinical studies are needed to verify efficacy.", "population_specificity": "Not specified (review of clinical and experimental studies from 1976-2013).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:54.914706+00:00"}
{"study_id": 101824, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of the receptor of advanced glycation end products (RAGE) in lung physiology and carcinogenesis, focusing on its differential expression and potential therapeutic implications.", "results_summary": "The study found that RAGE expression increases from fetal to adult life in lung epithelial cells but is rapidly downregulated upon malignant transformation, correlating with increased cancer aggressiveness. RAGE also functions as an adhesion molecule, stabilizing alveolar epithelial cells, and its reduction disrupts cell communication, promoting cancer progression.", "population_specificity": "Lung epithelial cells, with implications for lung cancer research.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:55.164507+00:00"}
{"study_id": 101825, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compile evidence on the molecular mechanisms of AGEs and oxidative stress (OS) and their influence, independently or combined, on the progression of nonalcoholic fatty liver disease (NAFLD).", "results_summary": "The study found that AGEs, particularly under hyperglycemia and lipid peroxidation, contribute to NAFLD progression by increasing oxidative stress and activating hepatic stellate cells, worsening liver fibrosis. The interaction between AGEs and their receptors enhances reactive oxygen species production, creating a vicious cycle that exacerbates disease.", "population_specificity": "Patients with or at risk of nonalcoholic fatty liver disease (NAFLD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:55.584067+00:00"}
{"study_id": 101826, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of convective therapies (including high-flux hemodialysis, hemofiltration, or hemodiafiltration) versus low-flux hemodialysis on the clearance of uremic solutes, including Advanced Glycation End Products, in patients with chronic kidney failure.", "results_summary": "Convective therapies improved the clearance of Advanced Glycation End Products and other solutes, reduced cardiovascular mortality and therapy-related hypotension, but did not significantly impact cardiac parameters, blood pressure, or anemia. The long-term benefits of specific convective modalities require further study.", "population_specificity": "Patients with chronic kidney failure", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:34:55.671290+00:00"}
{"study_id": 101828, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the mechanistic links between Advanced Glycation End Products (AGEs) and the connection between Alzheimer's disease (AD) and type-2 diabetes mellitus (T2DM).", "results_summary": "The study suggests that AGEs, along with other factors like hypercholesterolemia and inflammation, may act as molecular links between AD and T2DM, potentially contributing to \u03b2-amyloid accumulation and cerebrovascular inflammation. However, the details of these linkages require further investigation.", "population_specificity": "Patients with type-2 diabetes mellitus (T2DM) and Alzheimer's disease (AD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:00.359334+00:00"}
{"study_id": 101829, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the potential of medicinal herbs in attenuating and managing diabetic complications, focusing on their mechanisms related to hyperglycemia and oxidative stress.", "results_summary": "The review identified various medicinal plants and their active compounds (flavonoids, alkaloids, phenolic compounds, etc.) as effective in managing diabetic complications by ameliorating hyperglycemia, oxidative stress, and modulating metabolic pathways. However, further exploration of mechanisms, toxicity profiles, and development of better rodent models is needed.", "population_specificity": "Diabetic animals (specific human population not mentioned).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:00.960470+00:00"}
{"study_id": 101834, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether high-AGE diets and fructose intake affect insulin sensitivity in overweight individuals.", "results_summary": "The low-AGE diet reduced urinary AGEs, fasting insulin, and HOMA-IR compared to the high-AGE diet, suggesting AGEs may contribute to insulin resistance. Fructose intake did not influence outcomes.", "population_specificity": "Overweight women (n=74)", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:01.904099+00:00"}
{"study_id": 101831, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of anti-neuroinflammatory agents, including those targeting the receptor for advanced glycation end products, in attenuating microglial activation and cognitive decline for Alzheimer's disease treatment.", "results_summary": "The review highlights promising anti-neuroinflammatory agents that attenuate microglial activation or cognitive decline in vitro or in vivo, categorized by signaling pathways including advanced glycation end products. These agents support the development of anti-neuroinflammatory drugs for Alzheimer's disease.", "population_specificity": "Not specified (in vitro or in vivo studies, not human-specific).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:02.423300+00:00"}
{"study_id": 101832, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the biochemical properties and significance of DCXR activity in human diseases and the utility of C. elegans as a model to study DCXR biology.", "results_summary": "The abstract highlights DCXR's dual role in carbohydrate metabolism and detoxification, its association with diseases like pentosuria, cancers, diabetes, and male infertility, and proposes C. elegans as a model for further genetic analysis.", "population_specificity": "Not specified (focus on enzyme properties and model organisms).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:02.469841+00:00"}
{"study_id": 101836, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of pioglitazone and metformin on oxidative stress modulation, including the reduction of advanced glycation end products (AGEs).", "results_summary": "Pioglitazone was superior to no medication in reducing oxidative stress markers, including AGEs. Compared to metformin, both drugs were equally effective in reducing AGEs, but pioglitazone showed better efficacy in restoring certain enzymatic activities.", "population_specificity": "Newly diagnosed type 2 diabetes patients", "effective_dosage": "Pioglitazone 30mg daily, metformin 1000mg daily", "study_duration": "3 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:03.322837+00:00"}
{"study_id": 101835, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine the association between serum levels of soluble receptor for advanced glycation end products (sRAGE) and postoperative respiratory failure in cardiac surgery patients.", "results_summary": "Serum sRAGE levels increased significantly after cardiac surgery, with higher levels correlating with longer cardiopulmonary bypass duration and predicting postoperative respiratory failure (AUC 0.81). The optimal cutoff for predicting respiratory failure was 3656 pg/mL, with 62% sensitivity and 91% specificity.", "population_specificity": "87 patients undergoing elective cardiac surgery in three university hospitals.", "effective_dosage": "Not specified (measured serum levels, not administered).", "study_duration": "Biomarker levels measured perioperatively; clinical data collected for 7 days postoperatively; mechanical ventilation duration tracked for 28 days.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:04.291001+00:00"}
{"study_id": 101838, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in vascular remodeling, particularly their association with negative remodeling in diabetes.", "results_summary": "The study found that AGEs are key substances involved in negative vascular remodeling associated with diabetes, contributing to endothelial dysfunction and inflammation. The abstract suggests AGEs play a detrimental role in vascular health under diabetic conditions.", "population_specificity": "Not specified (general discussion of mechanisms in cardiovascular risk factors, including diabetes).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:08.797930+00:00"}
{"study_id": 101841, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to investigate the role of RAGE in mediating A\u03b2 cytotoxicity and its potential as a therapeutic target for Alzheimer's disease.", "results_summary": "The study found that RAGE mediates A\u03b2 cytotoxicity, leading to neuron damage and BBB dysfunction, and suggests that attenuating RAGE activity may prevent neurotoxicity and serve as a therapeutic strategy.", "population_specificity": "Not specified (likely in vitro or animal models based on context).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:08.974631+00:00"}
{"study_id": 101830, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the relationship between plasma AGE concentration and arterial stiffness in nondialyzed patients with diabetic nephropathy and those with chronic kidney disease (CKD) without diabetes.", "results_summary": "The study found that AGE concentration and arterial stiffness (measured by PWV) were significantly higher in patients with diabetic nephropathy compared to those without diabetes and controls. A significant correlation was observed between AGEs and PWV in CKD patients, but AGEs were not independently associated with PWV in multiple regression analysis.", "population_specificity": "24 patients with CKD and diabetic nephropathy, 36 patients with CKD without diabetes, and 19 controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:09.322271+00:00"}
{"study_id": 101837, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if skin advanced glycation end products (AGEs), measured via skin intrinsic fluorescence (SIF), could serve as a surrogate for multiyear mean HbA1c in predicting diabetes complications.", "results_summary": "The study found that SIF correlated with mean HbA1c, age, smoking status, renal function, skin tone, and clinic latitude, suggesting it reflects known risk factors for diabetes complications. Log(SIF) showed stronger associations with mean HbA1c over longer time periods.", "population_specificity": "1,185 individuals (53% male) with type 1 diabetes, mean age 51.5 years, mean diabetes duration 29.8 years.", "effective_dosage": "Not available", "study_duration": "Measurements taken during years 16/17 of the EDIC study.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:09.444682+00:00"}
{"study_id": 101839, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the levels of oxidative stress markers, including advanced glycation end-products (AGEs), in Alzheimer's disease (AD) patients compared to controls, and assess the impact of different treatments on these markers.", "results_summary": "Higher levels of advanced glycation end-products were observed in AD patients compared to controls, indicating increased oxidative stress. Treatment with Rivastigmine showed a reduction in IL-6 levels, but AGEs were not directly linked to treatment outcomes.", "population_specificity": "21 AD patients under standard treatment and 10 controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:09.786223+00:00"}
{"study_id": 101840, "supplement_id": 857, "safety_score": "90", "efficacy_score": 85, "quality_score": 75, "study_goal": "To examine the effects of alogliptin on glucose parameters, the AGE-RAGE axis, and albuminuria in Japanese type 2 diabetes patients.", "results_summary": "Alogliptin significantly improved glucose parameters, reduced circulating sRAGE and albuminuria, and increased 1,5-anhydroglucitol. AGEs were reduced only in patients with high baseline levels.", "population_specificity": "Japanese type 2 diabetes patients (mean age 64.7 years, 67% men, mean HbA1c 7.4%).", "effective_dosage": "25 mg once daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:10.898832+00:00"}
{"study_id": 101843, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to explore the harmful role of Advanced Glycation End Products (AGEs) in tissue components and investigate their potential link between periodontitis and diabetes mellitus (DM).", "results_summary": "The study suggests that AGEs, formed under chronic hyperglycemia, compromise tissue function by altering extracellular matrix components, potentially exacerbating periodontitis in DM patients. It highlights the need for novel therapeutic strategies targeting AGEs to treat periodontitis in DM subjects.", "population_specificity": "Subjects with diabetes mellitus (DM) and periodontitis.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:11.876468+00:00"}
{"study_id": 101842, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of cerebral glucose metabolism abnormalities, including potential links to Advanced Glycation End Products, in the pathophysiology of Alzheimer's disease (AD).", "results_summary": "The study proposed that impaired cerebral glucose metabolism contributes to AD through mechanisms like oxidative stress and mitochondrial dysfunction, highlighting insulin signaling impairment and thiamine metabolism abnormalities as key factors. Potential diagnostic biomarkers and therapeutic targets related to glucose metabolism were discussed.", "population_specificity": "Alzheimer's disease patients (theoretical/pathophysiological focus, not a clinical trial).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:12.538246+00:00"}
{"study_id": 101845, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize the molecular network of RAGE signaling, particularly its role in disease-related processes like inflammation, apoptosis, proliferation, and autophagy.", "results_summary": "The study highlights RAGE's upregulation in diseases such as diabetes, cardiovascular diseases, osteoarthritis, and cancer, and its regulation of critical cell processes. It also discusses therapeutic strategies to block RAGE and recent findings on novel signaling pathways activated by RAGE stimulation.", "population_specificity": "Not specified (review of existing studies, including RAGE transgenic mouse models)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:16.309057+00:00"}
{"study_id": 101844, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to review the pathological role of the AGEs/HMGB-1-RAGE system in various types of cardiovascular disease (CVD) and explore its potential as a therapeutic target.", "results_summary": "The study found that AGEs and their receptor RAGE play a central role in the pathogenesis of CVD, particularly in diabetes-related complications, by promoting inflammation and atherosclerosis. Administration of soluble RAGE (sRAGE) showed potential to inhibit AGE-RAGE interactions and prevent atherosclerosis in animal models.", "population_specificity": "Animal models and general discussion of diabetes-related CVD in humans.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:16.772238+00:00"}
{"study_id": 101848, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether simvastatin reduces inflammation and injury markers, including plasma receptor for advanced glycation end products, in patients undergoing esophagectomy.", "results_summary": "Simvastatin significantly reduced plasma receptor for advanced glycation end products and other biomarkers of inflammation and injury, though no significant difference was observed in the primary physiological outcome (Vd/Vt).", "population_specificity": "Patients undergoing esophagectomy", "effective_dosage": "80 mg enterally for 4 days preoperatively and 7 days postoperatively", "study_duration": "11 days total (4 pre-op, 7 post-op)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:17.628365+00:00"}
{"study_id": 101847, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to review the role of Advanced Glycation End Products (AGEs) in erectile dysfunction (ED), particularly in diabetes and aging, and evaluate potential interventions targeting AGE formation or activity.", "results_summary": "The review found that AGEs contribute to ED by affecting cavernous tissue, endothelial function, and molecular pathways, but clinical interventions targeting AGEs have shown disappointing results despite promising animal studies.", "population_specificity": "Primarily focused on individuals with diabetes and aging populations, as these conditions favor AGE formation and increase ED risk.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:17.792271+00:00"}
{"study_id": 101846, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to discuss the etiology of Alzheimer's disease (AD) and propose a paradigm shift in clinical trials, including the role of Advanced Glycation End Products in AD pathophysiology.", "results_summary": "The abstract mentions Advanced Glycation End Products as part of the complex pathophysiology of AD, but no specific results regarding its effects are detailed. The study emphasizes the need for polypharmacy and DSRS-driven pilot studies for AD pharmacotherapy screening.", "population_specificity": "AD patients, AD brain specimens, and animal studies.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:18.039167+00:00"}
{"study_id": 101849, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) as markers and potential contributors to diabetic complications, particularly retinopathy, nephropathy, and neuropathy.", "results_summary": "The study found that certain AGEs, especially the glucose/fructose-lysine/glucosepane axis, are robust markers for microvascular disease progression, particularly retinopathy, independent of glycemia levels. However, limited biological and clinical data on glucosepane highlight the need for further research.", "population_specificity": "Participants from the Diabetes Control and Complications Trial (DCCT), likely individuals with diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:19.207138+00:00"}
{"study_id": 101850, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to clarify the role of Advanced Glycation End Products (AGEs) in diabetic microvascular complications and their connection to metabolic memory.", "results_summary": "The study found that AGEs play a central role in diabetic neuropathy, retinopathy, and nephropathy by acting as \"directors\" of pathological processes, linking intracellular and extracellular damage and amplifying oxidative stress. This helps explain the clinical connection between micro- and macrovascular complications in diabetes.", "population_specificity": "Patients with type 2 diabetes, particularly those with microvascular complications.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:19.709713+00:00"}
{"study_id": 101851, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to review the mechanisms of cholesterol uptake, esterification, and release in macrophages to better understand macrophage foam cell formation in atherosclerosis.", "results_summary": "The abstract describes the roles of CD36, SR-A, ACAT1, nCEH, ABCA1, ABCG1, and SR-BI in cholesterol metabolism in macrophages, highlighting their contribution to foam cell formation in atherosclerosis. It does not directly address Advanced Glycation End Products.", "population_specificity": "Not specified (focus is on macrophage biology in atherosclerosis).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:20.716255+00:00"}
{"study_id": 101853, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether pioglitazone could reduce ADMA levels by decreasing RAGE expression in humans with impaired glucose tolerance or type 2 diabetes.", "results_summary": "Pioglitazone significantly decreased ADMA levels, improved insulin sensitivity, and elevated HDL-C and sRAGE levels, independent of glucose-lowering effects. The reduction in ADMA was correlated with changes in fibronectin, suggesting a protective role against cardiovascular disease.", "population_specificity": "48 patients with impaired glucose tolerance or type 2 diabetes", "effective_dosage": "Not specified", "study_duration": "16 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:24.677177+00:00"}
{"study_id": 101852, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize the role of oxidative stress, including Advanced Glycation End Products, in the pathogenesis of hematological malignancies and evaluate new oxidative stress markers.", "results_summary": "The abstract highlights the relationship between oxidative stress and hematological cancers, noting Advanced Glycation End Products as a stable and reliable marker of oxidative stress, but does not report specific efficacy or safety outcomes.", "population_specificity": "Patients with hematological malignancies (e.g., chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma) and those undergoing bone marrow transplantation.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:24.777059+00:00"}
{"study_id": 101854, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of microRNAs (miRNAs) in the pathobiology of diabetic complications, including the involvement of Advanced Glycation End Products (AGEs) in oxidant stress and their potential as diagnostic biomarkers and therapeutic targets.", "results_summary": "The abstract discusses the association of AGEs with diabetic complications but does not provide specific findings on their effects. It highlights the potential of miRNAs as biomarkers and therapeutic targets for complications linked to AGEs and oxidant stress.", "population_specificity": "Not specified (general discussion on diabetes complications)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:25.513648+00:00"}
{"study_id": 101856, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the role of AGE/ALE formation in diabetic retinopathy and evaluate inhibitors of the AGE-RAGE system for therapeutic utility.", "results_summary": "The abstract highlights that AGE/ALE formation contributes to retinal damage in diabetic patients and discusses potential therapeutic inhibitors of the AGE-RAGE system for diabetic retinopathy.", "population_specificity": "Diabetic patients with retinopathy", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:26.353458+00:00"}
{"study_id": 101857, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in diabetic nephropathy and evaluate potential therapeutic interventions targeting AGEs.", "results_summary": "The study highlights that AGEs contribute to diabetic nephropathy by promoting oxidative stress, inflammation, and fibrosis. Inhibitors of AGEs, such as pyridoxamine, were among the novel therapies tested to potentially prevent disease progression.", "population_specificity": "Patients with diabetic nephropathy or experimental diabetic models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:26.920546+00:00"}
{"study_id": 101855, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the role of Nox homologues in diabetic complications, including the impact of Advanced Glycation End Products (AGEs) on cell injury induced by hyperglycemia and other diabetes-related factors.", "results_summary": "The study found that AGEs, along with hyperglycemia and other factors, contribute to oxidative stress and cell injury in diabetic complications, with Nox homologues playing a critical role. Targeting NADPH oxidases, including Nox, with small-molecule inhibitors was proposed as a therapeutic approach to mitigate these complications.", "population_specificity": "Not specified (review of experimental animal models and general diabetic complications).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:27.020782+00:00"}
{"study_id": 101858, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of HMGB1 and its involvement in signaling mechanisms related to advanced glycation end-products (AGEs) in organ injury.", "results_summary": "The study found that HMGB1 is a key mediator of organ injury, contributing to both acute and chronic diseases through interactions with Toll-like receptors and AGE receptors. Strategies targeting HMGB1 and its pathways may offer preventive and therapeutic potential for organ injury.", "population_specificity": "Not specified (general organ injury mechanisms).", "effective_dosage": "Not available.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:27.665791+00:00"}
{"study_id": 101860, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to explore the association of advanced glycation end products (AGEs) with oxidative stress, metabolic profile, and atherosclerotic risk markers in prediabetic and diabetic elderly subjects.", "results_summary": "Higher levels of AGEs were found in prediabetic and diabetic groups, with strong positive associations with fasting glucose, HbA1c, insulin resistance, and atherosclerotic risk markers. AGEs, in combination with other biomarkers, may be valuable for predicting vascular complications and diabetes onset.", "population_specificity": "Elderly subjects with impaired fasting glucose (prediabetes, n=90), type 2 diabetes mellitus (n=95), and controls (n=88).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:33.082858+00:00"}
{"study_id": 101863, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of AGEs inhibitors from natural products as a preventive strategy for lifestyle-related diseases like diabetic complications and atherosclerosis.", "results_summary": "The study found that AGEs inhibitors (e.g., benfotiamine, pyridoxamine, aminoguanidine) significantly inhibited retinopathy and neuropathy in diabetic rats, suggesting their potential for preventing diabetic complications. The abstract also highlights the preference for natural dietary sources of AGEs inhibitors over prescribed drugs.", "population_specificity": "Streptozotocin-induced diabetic rats", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:33.681826+00:00"}
{"study_id": 101861, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to analyze the effects of rosiglitazone on circulating biomarkers, including soluble receptor for advanced glycation end products (sRAGE), in subjects with type 2 diabetes at high risk for coronary artery disease.", "results_summary": "Rosiglitazone favorably increased sRAGE levels (inversely associated with atherosclerosis) from 1.1 to 1.4 ng/mL (P = .003), while placebo showed a smaller change (1.0 to 1.1 ng/mL, P = .046). No other biomarkers related to advanced glycation end products were significantly affected by rosiglitazone.", "population_specificity": "Subjects with type 2 diabetes and high risk for coronary artery disease (mean age 56, 41% women, 66% nonwhite).", "effective_dosage": "Not specified", "study_duration": "6 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:34.139963+00:00"}
{"study_id": 101865, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the association between thiamine and Parkinson's disease (PD), including the role of Advanced Glycation End Products in PD pathology.", "results_summary": "The abstract suggests a significant association between low serum thiamine levels and PD, with thiamine supplements showing beneficial clinical effects. Advanced Glycation End Products were identified as one of the candidate pathways involved in PD pathology.", "population_specificity": "Elderly individuals with Parkinson's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:34.201651+00:00"}
{"study_id": 101862, "supplement_id": 857, "safety_score": "30", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effects of glucose and glucose degradation products (GDPs) in peritoneal dialysis solutions, particularly their role in forming advanced glycation end-products (AGEs) and associated complications.", "results_summary": "The study found that glucose absorption in peritoneal dialysis leads to metabolic complications, oxidative stress, and peritoneal membrane damage, while GDPs promote AGE formation, contributing to microvascular complications and arteriosclerosis. Clinical studies on low-GDP solutions showed mixed results regarding residual renal function, peritonitis, and mortality.", "population_specificity": "Patients undergoing peritoneal dialysis, particularly those with type 2 diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:34.204372+00:00"}
{"study_id": 101864, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 60, "study_goal": "The researchers aimed to explore the systemic and local toxic effects of advanced glycation end-products (AGEs) in the context of diabetic wound healing and chronic inflammation.", "results_summary": "The study found that AGEs irreversibly impair cellular and organ physiology, hinder fibroblast and endothelial cell function, and contribute to chronic inflammation and poor wound healing in diabetic patients.", "population_specificity": "Patients with Type 2 diabetes mellitus predisposed to lower extremity ulceration and impaired wound healing.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:35.789369+00:00"}
{"study_id": 101866, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in the pathogenesis of chronic kidney disease (CKD) and uremia, and hypothesize the therapeutic potential of probiotics and prebiotics in mitigating these effects.", "results_summary": "The study suggests that AGEs, along with other toxins generated in or introduced via the intestine, may contribute to CKD progression, but does not provide specific experimental results on AGEs' effects. It proposes that probiotics and prebiotics could help maintain gut metabolic balance and reduce CKD progression.", "population_specificity": "Patients with chronic kidney disease (CKD) and uremia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:36.501013+00:00"}
{"study_id": 101859, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the common pathophysiological and clinical similarities between Alzheimer's disease (AD) and diabetes mellitus (DM), particularly focusing on the role of advanced glycation end products (AGEs) in both conditions.", "results_summary": "The study found that AD and DM share multiple common denominators, including defective insulin signaling, impaired glucose uptake, increased oxidative stress, and elevated AGE formation, suggesting potential therapeutic overlap. It proposed that existing DM treatments, such as insulin and oral hypoglycemic agents, might be repurposed for AD management.", "population_specificity": "Global populations affected by Alzheimer's disease and diabetes mellitus, primarily senior citizens for AD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:39.895685+00:00"}
{"study_id": 101867, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 60, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in hyperglycemia-induced oxidative stress and its contribution to diabetic cardiovascular complications.", "results_summary": "The study found that AGEs, along with other pathways, contribute to reactive oxygen species (ROS) accumulation, leading to cellular damage, endothelial dysfunction, and vascular complications in diabetes. However, clinical evidence on antioxidant therapies for these complications remains inconclusive.", "population_specificity": "Individuals with diabetes mellitus (specific population details not provided).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:40.780969+00:00"}
{"study_id": 101870, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in diabetic heart failure and investigate potential therapeutic interventions targeting AGE-RAGE interactions.", "results_summary": "The study found that AGEs contribute to diabetic heart failure by promoting oxidative stress, inflammation, and extracellular matrix accumulation, leading to vascular and myocardial damage. Drug therapies targeting AGE-RAGE interactions show promise in mitigating myocardial injury.", "population_specificity": "Diabetic patients with or at risk of heart failure.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:42.135885+00:00"}
{"study_id": 101869, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore factors associated with genetic damage in chronic kidney disease (CKD) patients, including the role of advanced glycation end products (AGEs) as markers of oxidative stress.", "results_summary": "The study found that CKD patients, particularly those on peritoneal dialysis, had higher levels of genetic damage, with AGEs being one of the oxidative stress markers elevated in patients with higher micronucleus frequency. No significant difference was observed in haemodialysis patients compared to controls.", "population_specificity": "91 CKD patients (pre-dialysis, peritoneal dialysis, haemodialysis) and 61 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Cross-sectional study (no intervention duration specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:43.004694+00:00"}
{"study_id": 101868, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of 12-week resistance training on collagen and RAGE presence in skeletal muscle of knee osteoarthritis patients, particularly in relation to NSAID and glucosamine use.", "results_summary": "Resistance training increased type IV collagen immunoreactivity in most patients and reduced type I collagen in glucosamine-treated patients. RAGE levels significantly increased in the placebo group but were attenuated by glucosamine.", "population_specificity": "Patients aged 55-69 with knee osteoarthritis, divided into NSAID, glucosamine, or placebo groups.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:43.416095+00:00"}
{"study_id": 101871, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to evaluate the direct effects of HMGB1 on the in vitro response of urothelial carcinoma cells to bacillus Calmette-Gu\u00e9rin.", "results_summary": "HMGB1 potentiated the cytotoxic effects of bacillus Calmette-Gu\u00e9rin and activated key signaling pathways (NF\u03baB, NRF2, CEBP), enhancing gene expression and tumor cell response. Blockade of HMGB1 or its receptor (RAGE) significantly reduced these effects.", "population_specificity": "Human urothelial carcinoma cell lines", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:43.864439+00:00"}
{"study_id": 101872, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the effects of dietary sweet cherries on plasma concentrations of biomarkers related to chronic inflammatory diseases, including Advanced Glycation End Products.", "results_summary": "Cherry consumption significantly reduced plasma concentrations of several inflammatory biomarkers, including a 29.0% decrease in extracellular newly identified ligand for the receptor for advanced glycation end products (EN-RAGE). No adverse effects were reported.", "population_specificity": "18 healthy men and women aged 45-61 with modestly elevated CRP (1-14 mg/L).", "effective_dosage": "280 g/day of Bing sweet cherries.", "study_duration": "28 days of intervention, with follow-up measurements at 28 days post-discontinuation.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:43.922987+00:00"}
{"study_id": 101873, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if plasma S100A12 levels could predict two-year all-cause mortality in hemodialysis patients and establish a scoring system for clinical use.", "results_summary": "Higher plasma S100A12 levels (\u226518.79 ng/mL) were significantly associated with increased all-cause mortality, alongside other factors like age, low serum albumin, and CVD history. The scoring system demonstrated good discriminative power for predicting mortality.", "population_specificity": "550 maintenance hemodialysis patients (with a validation cohort of 303).", "effective_dosage": "Not applicable (study measured plasma levels, not administered dosage).", "study_duration": "Two-year follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:44.957870+00:00"}
{"study_id": 101874, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to explore the potential beneficial role of vitamin D, particularly calcitriol, in modulating advanced glycation end products (AGEs) and its effects on Alzheimer's disease (AD).", "results_summary": "The study suggests that vitamin D supplements, especially calcitriol, may benefit AD by modulating AGEs, among other mechanisms, though further investigation is needed.", "population_specificity": "Elderly individuals with Alzheimer's disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:47.615140+00:00"}
{"study_id": 101875, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of RAGE and its splicing variants in various pathophysiological processes and their potential implications in human and canine diseases.", "results_summary": "The study found that RAGE and its isoforms play significant roles in immune/inflammatory disorders, Alzheimer's disease, diabetic arteriosclerosis, tumorigenesis, and metastasis, with deregulated expression linked to several pathological conditions. Soluble RAGE isoforms were particularly highlighted in research and clinical contexts.", "population_specificity": "Humans and canines (comparative analysis).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:49.828098+00:00"}
{"study_id": 101876, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to investigate the association between Advanced Glycation End Products (AGEs) and their receptors (RAGE) with plaque volume (PV) in patients with acute coronary syndrome (ACS).", "results_summary": "High baseline AGEs levels were associated with plaque progression, independent of diabetes mellitus (DM). Statin therapy reduced AGEs levels but did not correlate with changes in PV or sRAGE.", "population_specificity": "Patients with ACS undergoing intravascular ultrasound-guided percutaneous coronary intervention (PCI).", "effective_dosage": "4 mg/day of pitavastatin or 20 mg/day of atorvastatin.", "study_duration": "8-12 months after PCI.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:52.149440+00:00"}
{"study_id": 101878, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to summarize recent advances in the therapy of diabetic neuropathy, including the role of Advanced Glycation End Products (AGEs) inhibition through benfotiamine.", "results_summary": "The study highlights that benfotiamine inhibits AGE formation by targeting key alternative pathways (polyol, hexosamine, protein-kinase-C) and activating transketolase, suggesting a potential therapeutic role in diabetic neuropathy.", "population_specificity": "Patients with diabetic neuropathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:52.354363+00:00"}
{"study_id": 101879, "supplement_id": 857, "safety_score": "30", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the acute effects of AGE-modified \u03b2-lactoglobulins (AGE-BLG) on vascular function in patients with type 2 diabetes mellitus (T2DM), comparing it to non-glycated BLG (C-BLG).", "results_summary": "AGE-BLG significantly impaired macrovascular function (reduced flow-mediated dilation) and decreased nitric oxide bioavailability, while microvascular function remained unaffected. The effects were transient but more pronounced than those caused by C-BLG.", "population_specificity": "19 patients with type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified (beverage containing AGE-BLG or C-BLG).", "study_duration": "Acute effects measured at 90 and 180 minutes post-administration.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:52.536014+00:00"}
{"study_id": 101881, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to summarize clinical data on the role of Advanced Glycation End Products (AGEs) and their receptor (RAGE) in hypertension and vascular disease.", "results_summary": "The study found no evidence linking the AGE-RAGE axis to hypertension but suggested a role in vascular disease, including macrocirculation and microcirculation. It highlighted the need for more interventional trials to explore AGEs' impact on vascular health.", "population_specificity": "Diabetic subjects and individuals with vascular disease (clinical focus, excluding animal data).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:52.939481+00:00"}
{"study_id": 101880, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to assess whether lifestyle intervention combined with Vitamin E supplementation reduces oxidative stress and improves cardio-metabolic status in obese children with NAFLD, focusing on markers like esRAGE.", "results_summary": "Vitamin E supplementation significantly reduced oxidative stress (PGF2-\u03b1) and improved cardio-metabolic markers (esRAGE, ALT, lipid profile, HOMA-IR) compared to lifestyle intervention alone. No significant changes were observed in the control group.", "population_specificity": "Obese prepubertal children (24 treated, 21 controls) with NAFLD.", "effective_dosage": "600 mg/day of Vitamin E.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:53.230896+00:00"}
{"study_id": 101882, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) and the renin-angiotensin system (RAS) in diabetic retinopathy and their potential interactions for new treatment strategies.", "results_summary": "The study found that both AGEs and RAS influence diabetic retinopathy, with growing evidence of cross-talk between these pathways, suggesting potential implications for developing new treatments.", "population_specificity": "Patients with diabetic retinopathy (pre-clinical and clinical studies referenced).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:55.545233+00:00"}
{"study_id": 101883, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to investigate the changes in skin autofluorescence (SAF) levels of Advanced Glycation End Products (AGEs) during pregnancy in diabetic and non-diabetic women and assess its relation to adverse pregnancy outcomes.", "results_summary": "SAF decreased slightly during normal pregnancy but not in hyperglycemic pregnancies. SAF was higher in preexistent DM patients compared to GDM and controls but showed no association with adverse pregnancy outcomes.", "population_specificity": "79 GDM patients, 21 preexistent DM (type 1 or 2) patients, and 55 non-diabetic pregnant women.", "effective_dosage": "Not specified", "study_duration": "Measured from 26 gestational weeks onward until the end of pregnancy.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:35:58.851968+00:00"}
{"study_id": 101887, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) and other diabetes-induced metabolites in the pathophysiology of diabetic cardiomyopathy (DCM).", "results_summary": "The abstract discusses AGEs as one of several factors implicated in DCM but does not provide specific findings on their effects. The review highlights the need for further understanding of molecular mechanisms to develop effective therapies.", "population_specificity": "Diabetic population, particularly those at risk for or with diabetic cardiomyopathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:00.933231+00:00"}
{"study_id": 101885, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in the progression of diabetic nephropathy, particularly their involvement in inflammation pathways and potential as therapeutic targets.", "results_summary": "The study identified AGEs as one of the three major pathways contributing to diabetic nephropathy, linking them to microinflammation and extracellular matrix expansion. It suggested that targeting inflammatory molecules related to AGEs could lead to new therapeutic strategies for diabetic nephropathy.", "population_specificity": "Patients with diabetic nephropathy, chronic kidney disease (CKD), and end-stage renal disease (ESRD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:00.935498+00:00"}
{"study_id": 101884, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of RAGE (receptor for advanced glycation end-products) in various pathological and physiological processes, including inflammation, tissue repair, and disease progression.", "results_summary": "The study found that RAGE activation is involved in both pathological conditions (e.g., diabetes, neurodegeneration, cancer) and physiological processes (e.g., tissue homeostasis, inflammation resolution). Its effects vary by cell type and context, influencing potential therapeutic strategies.", "population_specificity": "Not specified (basic research on molecular mechanisms).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:01.107910+00:00"}
{"study_id": 101886, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the association between serum levels of glycated albumin (GA), sRAGE, esRAGE, and the severity of albuminuria, CI-AKI occurrence, and 1-year clinical outcomes in type 2 diabetic patients undergoing percutaneous coronary intervention.", "results_summary": "Elevated GA and reduced sRAGE/esRAGE levels correlated with increased albuminuria severity and higher CI-AKI incidence, negatively impacting 1-year clinical outcomes. These markers remained independently associated with adverse events after adjusting for confounders.", "population_specificity": "Type 2 diabetic patients undergoing sirolimus-eluting stent-based percutaneous coronary intervention, stratified by albuminuria severity (normoalbuminuria, microalbuminuria, macroalbuminuria).", "effective_dosage": "Not specified", "study_duration": "1-year follow-up", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:01.985268+00:00"}
{"study_id": 101888, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether Advanced Glycation End Products (AGEs) induce endoplasmic reticulum (ER) stress and studied the ER stress-activated pathways that stimulate cyclooxygenase-2 (COX-2) expression in human chondrocytes.", "results_summary": "AGE-BSA induced ER stress markers (GRP78, Bag-1) and COX-2 expression in human chondrocytes, mediated through eIF2\u03b1, p38-MAPK, and NF-\u03baB pathways. RAGE knockdown and specific inhibitors (eIF2\u03b1, SB202190, Bay 11-7082) suppressed these effects, while other inhibitors (PD98051, SP600125) had partial or no impact.", "population_specificity": "Human chondrocytes", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:02.402521+00:00"}
{"study_id": 101877, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine the role of plasma sRAGE and HMGB1 in acute ischemic stroke (IS) patients and mice, and whether recombinant sRAGE could be a potential therapeutic agent.", "results_summary": "Plasma levels of sRAGE and HMGB1 increased significantly after IS, with sRAGE being an independent predictor of functional outcome. Recombinant sRAGE administration reduced immune cell infiltration, improved injury outcomes in mice, and protected neurons from oxygen-glucose deprivation-induced cell death.", "population_specificity": "Acute ischemic stroke patients and C57BL/6J mice subjected to focal ischemic stroke.", "effective_dosage": "Not specified", "study_duration": "Plasma samples collected within 48 hours post-stroke; intervention duration in mice not specified.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:02.407253+00:00"}
{"study_id": 101889, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate whether benfotiamine, a thiamine derivative, could mitigate the effects of advanced glycation end products (AGEs) in Alzheimer's Disease (AD) and diabetes by enhancing thiamine-dependent metabolic pathways.", "results_summary": "The study found that benfotiamine reduced AGE accumulation in diabetes, improved thiamine-dependent enzyme activity, and reversed AD-related pathology (e.g., plaque formation, tau phosphorylation, and memory deficits) in animal models.", "population_specificity": "Animal models (mice) and diabetic humans (peripheral neuropathy context).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:04.811066+00:00"}
{"study_id": 101890, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to examine the relationship between skin autofluorescence (a marker of advanced glycation end-products) and cardiovascular risk factors in children with chronic kidney disease.", "results_summary": "The study found that skin autofluorescence (sAF) was elevated in children with chronic kidney disease and was associated with cardiovascular risk markers such as arterial stiffness, left ventricular mass, blood pressure, and biochemical factors like phosphate and homocysteine. sAF also correlated with dialysis duration and declining kidney function.", "population_specificity": "Children with chronic kidney disease (20 on hemodialysis, 20 on peritoneal dialysis, 36 treated conservatively) and 26 healthy controls.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:07.035532+00:00"}
{"study_id": 101892, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to summarize the clinical utility of AGE cross-link breakers in preventing and managing age- and diabetes-associated disorders.", "results_summary": "The study found that AGEs contribute to vascular and myocardial stiffness, organ dysfunction, and various diseases via oxidative stress and inflammation. AGE cross-link breakers show promise as a therapeutic approach for these conditions.", "population_specificity": "General aging population and individuals with diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:08.244898+00:00"}
{"study_id": 101893, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) in cartilage damage and their systemic inflammatory effects in metabolic osteoarthritis.", "results_summary": "The study found that AGEs contribute to cartilage damage through oxidative stress and local effects, while systemic inflammation from glucose accumulation exacerbates osteoarthritis. AGEs are implicated in the toxic internal environment that worsens OA progression.", "population_specificity": "Patients with metabolic osteoarthritis and metabolic syndrome.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:09.410428+00:00"}
{"study_id": 101891, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to determine whether levels of AGE-LDL in immune complexes predict incident cardiovascular disease events in patients with type 2 diabetes.", "results_summary": "The study found that higher levels of MDA-LDL in immune complexes were associated with increased risk of myocardial infarction and composite cardiovascular events, while AGE-LDL showed modest but less consistent associations (HR = 1.31 for MI and 1.34 for composite endpoint).", "population_specificity": "907 patients with type 2 diabetes from the VADT cohort.", "effective_dosage": "Not specified", "study_duration": "Median follow-up of 3.7 years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:09.769945+00:00"}
{"study_id": 101894, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the role of Ca(2+) signaling and oxidative stress, including the involvement of Advanced Glycation End Products, in diabetic neuropathic pain in sensory neurons.", "results_summary": "The study found that Advanced Glycation End Products, along with oxidative stress and Ca(2+) dysregulation, contribute to diabetic neuropathic pain. It highlighted the potential of modulating neuronal Ca(2+) handling as a therapeutic approach for diabetic neuropathies.", "population_specificity": "Patients with diabetes mellitus, particularly those with peripheral neuropathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:11.013566+00:00"}
{"study_id": 101895, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to summarize the characteristics of RAGE, its isoforms, ligands, and signaling pathways in the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), and explore its potential as a therapeutic target.", "results_summary": "The abstract highlights RAGE's role in inflammation and infection response, its activation of NF-\u03baB leading to proinflammatory cytokine expression, and the inhibitory role of soluble RAGE (sRAGE). It also notes enhanced RAGE expression in inflammatory states like ALI/ARDS.", "population_specificity": "Not specified (general review of RAGE in ALI/ARDS pathogenesis).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:12.111398+00:00"}
{"study_id": 101896, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether r-roscovitine treatment could reduce lung damage in ventilator-induced lung injury (VILI) by targeting polymorphonuclear neutrophil (PMN) apoptosis and lowering markers like RAGE (receptor for advanced glycation end products).", "results_summary": "R-roscovitine treatment reduced PMN influx and lowered RAGE and total immunoglobulin M levels in bronchoalveolar lavage fluid during lung-injurious mechanical ventilation, suggesting a protective effect against VILI. However, it did not affect cytokine or chemokine levels in the bronchoalveolar space.", "population_specificity": "Mouse model of ventilator-induced lung injury (VILI)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:12.885611+00:00"}
{"study_id": 101897, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize current understanding of hyperglycemia-induced cardiac mitochondrial dysfunction, focusing on oxidative stress and the role of p66Shc protein.", "results_summary": "The abstract highlights that hyperglycemia drives diabetic cardiovascular complications through mechanisms like advanced glycation end-products formation and oxidative stress, with p66Shc protein playing a key role in mitochondrial oxidative balance.", "population_specificity": "Not specified (general discussion of diabetes-related mechanisms)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:13.543897+00:00"}
{"study_id": 101898, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to examine the role of advanced glycation end-products (AGEs) in cardiovascular disease (CVD) risk in diabetes and evaluate the potential of soluble RAGE as a marker for CVD.", "results_summary": "The study suggests that AGEs, through binding to RAGE, contribute to vascular damage by inducing cytokine production and oxidative stress. However, data on soluble RAGE as a CVD marker are sparse and conflicting.", "population_specificity": "Not specified (general focus on diabetes and cardiovascular disease mechanisms).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:15.159200+00:00"}
{"study_id": 101900, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the relevance of serum nucleosomes, HMGB1, and sRAGE as biomarkers for diagnosis, prognosis, and therapy prediction in cancer.", "results_summary": "Cancer patients had elevated serum levels of nucleosomes and HMGB1 but decreased sRAGE levels. High nucleosome and HMGB1 release, along with low sRAGE release during therapy, were associated with poor treatment response and survival.", "population_specificity": "Cancer patients undergoing locoregional and systemic cytotoxic therapies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:16.885130+00:00"}
{"study_id": 101899, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) and their receptors (RAGE) in the pathogenesis of Alzheimer's disease (AD), focusing on blood-brain barrier (BBB) dysfunction and potential therapeutic strategies.", "results_summary": "The study found that BBB dysfunction in AD involves RAGE-mediated influx and LRP1-mediated efflux of amyloid-\u03b2-peptide (ABP), suggesting that targeting these pathways could regulate ABP levels in the brain. Nanodrug delivery was proposed as a potential therapeutic strategy to enhance drug delivery and neuroprotection in AD.", "population_specificity": "The study discusses Alzheimer's disease pathology broadly, without specifying a particular human or animal population.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:17.260325+00:00"}
{"study_id": 101902, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review drugs targeting advanced glycation end products (AGEs) to treat diabetic kidney disease (DKD) by interrupting pathologic mechanisms.", "results_summary": "Ten drugs showed beneficial effects in DKD patients, improving markers like glomerular filtration rate and proteinuria, while five demonstrated no significant benefit or prohibitive side effects. Further large-scale trials are needed to confirm these findings.", "population_specificity": "Patients with diabetic kidney disease (DKD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:18.180647+00:00"}
{"study_id": 101901, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of the receptor for advanced glycation end products (RAGE) in mediating HMGB1-induced neuroinflammation and necrosis in neurological diseases.", "results_summary": "The study found that RAGE and Toll-like receptors mediate HMGB1-induced neuroinflammation and necrosis, with HMGB1 acting as both a protective factor in Huntington's disease and a risk factor in Alzheimer's, Parkinson's, and multiple sclerosis.", "population_specificity": "Vertebrate cells, particularly in the central nervous system during development and adulthood.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:18.667459+00:00"}
{"study_id": 101903, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the inhibitory effect of L-Lysine on the nonenzymatic glycation of fibrinogen in both in vitro and in vivo conditions.", "results_summary": "The study found that glycation increased fibrinogen activity and altered its structure, while L-Lysine inhibited these changes, improving fibrinogen's structure and function in both experimental settings.", "population_specificity": "Type 2 diabetic patients (in vivo) and in vitro experiments with fibrinogen.", "effective_dosage": "Not specified", "study_duration": "3 months (in vivo)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:19.639858+00:00"}
{"study_id": 101905, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of inflammatory mediators, including Advanced Glycation End Products, in the pathogenesis of PCOS and their connection with low-grade inflammation.", "results_summary": "The abstract mentions Advanced Glycation End Products as one of the mediators discussed, but no specific results or effects related to them are detailed.", "population_specificity": "Reproductive-age women with polycystic ovarian syndrome (PCOS).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:20.074922+00:00"}
{"study_id": 101904, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of RAGE in inflammatory disorders, tumor growth, diabetic complications, and Alzheimer's disease, and its potential as a therapeutic target.", "results_summary": "The study found that RAGE transports amyloid-\u03b2 toxins across the blood-brain barrier, leading to oxidative stress, inflammation, and reduced cerebral blood flow. Regulating RAGE activity could benefit Alzheimer's patients, though recent RAGE-based therapies have faced setbacks.", "population_specificity": "Not specified (discusses general mechanisms and potential treatments).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:21.420834+00:00"}
{"study_id": 101907, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to review the role of AGEs, particularly dietary AGEs, in ESRD patients and explore potential anti-AGE therapeutic strategies.", "results_summary": "The abstract highlights AGEs' implications in aging, neurodegenerative diseases, diabetes, and chronic kidney disease but notes a lack of prospective human studies on AGEs in chronic renal replacement therapy patients. It emphasizes the need for therapeutic strategies to address ESRD progression and outcomes.", "population_specificity": "End-stage renal disease (ESRD) patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:24.283181+00:00"}
{"study_id": 101909, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review the role of Advanced Glycation End Products (AGEs) in diabetic vascular complications and explore regenerative therapies for diabetic microangiopathy.", "results_summary": "The abstract highlights that AGEs contribute to vascular injury in diabetes through mechanisms like oxidative stress and nitric oxide reduction, leading to arterial remodeling and atherosclerosis. It mentions pharmacological therapies, growth factors, and stem cell strategies as effective approaches for treating diabetic microangiopathy.", "population_specificity": "Diabetic patients with vascular complications (e.g., peripheral arterial disease, coronary heart disease, ischemic stroke).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:25.695862+00:00"}
{"study_id": 101910, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of advanced glycation end products (AGEs) in endoplasmic reticulum (ER) stress and their potential contribution to metabolic diseases.", "results_summary": "The study found that AGEs, along with hyperglycemia, hypoxia, and oxidative stress, can induce ER stress, leading to pathogenic conditions. Inhibitors of AGEs may help restore ER homeostasis and present a promising therapeutic approach for metabolic dysfunction.", "population_specificity": "Not specified (review of basic and clinical studies)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:26.175166+00:00"}
{"study_id": 101906, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of miRNAs in the pathology of diabetic complications and discuss their potential as diagnostic and therapeutic targets.", "results_summary": "The abstract does not provide specific findings about Advanced Glycation End Products but highlights their role as a contributing factor to diabetic complications alongside other factors like hyperglycemia and inflammatory cytokines.", "population_specificity": "Not specified (general discussion of diabetic complications in Type 1 and Type 2 diabetes).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:27.164731+00:00"}
{"study_id": 101912, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the expression patterns of HMGB1 and RAGE (receptor for advanced glycation end products) in rat and human brains following traumatic brain injury (TBI).", "results_summary": "HMGB1 levels initially declined after TBI but returned to baseline, while RAGE expression increased and remained elevated. Both HMGB1 and RAGE showed dynamic localization changes in microglia post-TBI, suggesting their involvement in the injury response.", "population_specificity": "Rats and human brains post-TBI.", "effective_dosage": "Not specified.", "study_duration": "Observations were made up to 6 days post-TBI in rats.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:27.973258+00:00"}
{"study_id": 101911, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of the receptor for advanced glycation end products (RAGE) in asthma and COPD, focusing on its involvement in inflammation and potential therapeutic targeting.", "results_summary": "The study found increased RAGE and its ligands in chronic airways disease, along with reduced soluble RAGE, suggesting a role in inflammation. It highlights RAGE as a potential therapeutic target but does not establish definitive clinical outcomes.", "population_specificity": "Patients with asthma and chronic obstructive pulmonary disease (COPD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:30.037065+00:00"}
{"study_id": 101908, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to compare the effects of two initial insulin strategies (basal insulin alone vs. premixed insulin) on post-prandial glucose metabolism and precursors of advanced glycation end-products in type 2 diabetes patients poorly controlled on oral anti-hyperglycemic drugs.", "results_summary": "Premixed insulin (lispro mix) significantly improved post-prandial glucose levels and reduced fasting and post-prandial 3-deoxyglucosone (3-DG), a precursor of advanced glycation end-products, compared to basal insulin (glargine). No differences were observed in methylglyoxal (MG) concentrations.", "population_specificity": "Type 2 diabetes patients suboptimally controlled on oral anti-hyperglycemic drugs.", "effective_dosage": "Once daily insulin glargine or twice-daily 75%/25% neutral protamine lispro/lispro mix.", "study_duration": "6 months (with a 12-week cross-over period for each regimen).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:30.388002+00:00"}
{"study_id": 101913, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of advanced glycation end products (AGEs) as a nontraditional risk factor in vascular calcification, particularly in patients with chronic kidney disease (CKD).", "results_summary": "The study found that AGEs, along with oxidative stress and disordered mineral metabolism, are more prevalent and severe in CKD patients, contributing to the pathogenesis of vascular calcification. These factors are associated with increased coronary artery calcification in CKD patients compared to the general population.", "population_specificity": "Patients with chronic kidney disease (CKD) and the general population.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:31.909636+00:00"}
{"study_id": 101914, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effect of nifedipine-telmisartan combination therapy on sRAGE plasma levels in hypertensive patients with high cardiovascular risk.", "results_summary": "The study found that nifedipine-telmisartan treatment significantly increased sRAGE plasma concentrations after 24 weeks, suggesting potential atheroprotective and anti-inflammatory effects. sRAGE levels were not influenced by microalbuminuria or GFR in these patients.", "population_specificity": "Hypertensive patients with high cardiovascular risk and early-stage renal disease.", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:32.917581+00:00"}
{"study_id": 101915, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether sevelamer carbonate could sequester cytotoxic AGEs in the gut, preventing their uptake and reducing AGE-induced abnormalities in diabetic CKD patients.", "results_summary": "Sevelamer carbonate reduced HbA1c, serum methylglyoxal, triglycerides, and markers of inflammation and oxidative stress while increasing antioxidant markers. It also reversibly bound AGE-BSA at intestinal pH but not stomach pH.", "population_specificity": "Stage 2-4 diabetic CKD patients.", "effective_dosage": "Not specified", "study_duration": "2 months per treatment (with a 1-week washout between treatments)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:33.675436+00:00"}
{"study_id": 101916, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of the RAGE-ligand axis in heart failure and assess its potential as a therapeutic target.", "results_summary": "The study found that RAGE and its ligands are upregulated in heart injuries like ischemia/reperfusion, diabetes, and inflammation. Pharmacological or genetic inhibition of RAGE showed protective effects in animal models, and human studies suggested a correlation between RAGE ligand levels and heart failure severity.", "population_specificity": "Murine, rat, swine models, and human studies (plasma/serum analysis).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:33.827186+00:00"}
{"study_id": 101918, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) as biomarkers for diabetes and its vascular complications, and their potential in early detection and treatment.", "results_summary": "The study highlights that AGEs, formed due to hyperglycemia and dyslipidemia, can serve as biomarkers for diabetes and its complications. Noninvasive technologies like skin autofluorescence can detect AGE-mediated tissue damage, offering potential for early intervention.", "population_specificity": "Not specified (general discussion on diabetes and its complications)", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:35.662668+00:00"}
{"study_id": 101917, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of copper dysregulation and Advanced Glycation End Products (AGEs) in diabetes-related organ damage and explore the therapeutic potential of triethylenetetramine (TETA) as a copper chelator.", "results_summary": "The study found that AGEs contribute to pathogenic structures in blood vessels, binding catalytically-active CuII, and that copper dysregulation mediates organ damage through oxidative stress and impaired antioxidant defenses. TETA, as a selective CuII chelator, showed potential in reversing copper dysregulation and preventing organ damage.", "population_specificity": "Patients with diabetes, heart failure, and neurodegenerative diseases (inferred from nonclinical studies and proof-of-principle clinical trials).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:36.023657+00:00"}
{"study_id": 101919, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to summarize recent advances in understanding the role of Advanced Glycation End Products (AGEs) in neurodegenerative diseases, particularly Alzheimer's and Parkinson's diseases.", "results_summary": "The study found that AGEs contribute to the abnormal deposition and accumulation of proteins, which sustains oxidative stress and inflammatory responses, leading to neurodegenerative disease pathology. The extent of glycation correlates with disease severity in patients.", "population_specificity": "Patients with neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:38.149162+00:00"}
{"study_id": 101920, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) in peritoneal membrane damage during long-term peritoneal dialysis (PD) and explore potential interventions like benfotiamine (BF) and glyoxalase.", "results_summary": "The study found that AGEs contribute to peritoneal membrane damage and fibrosis in both rodents and humans during PD. Interventions like BF showed success in mitigating kidney damage, suggesting potential systemic benefits beyond local peritoneal effects.", "population_specificity": "Rodents and humans undergoing long-term peritoneal dialysis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:38.687064+00:00"}
{"study_id": 101923, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the role of methylglyoxal-derived advanced glycation end products (AGEs) in the healing process of diabetic gastric ulcers.", "results_summary": "The study found that methylglyoxal modification of peroxiredoxin-VI is associated with delayed healing of diabetic gastric ulcers, suggesting that inhibiting this modification could have therapeutic potential.", "population_specificity": "Diabetic individuals with gastric ulcers.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.336478+00:00"}
{"study_id": 101921, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to propose a novel dual-target nanoparticle-based treatment for diabetic nephropathy by targeting AGEs and RAGE.", "results_summary": "The study suggests that AGEs and RAGE play a key role in diabetic nephropathy pathogenesis and proposes a dual-target nanoparticle approach to inhibit AGEs and RAGE, potentially improving treatment efficacy.", "population_specificity": "Diabetic nephropathy patients (hypothetical, as this is a proposal).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.744033+00:00"}
{"study_id": 101924, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review potential therapeutic interventions, including targeting Advanced Glycation End Products (AGEs), to prevent or delay diabetic nephropathy progression.", "results_summary": "The abstract highlights AGEs as a potential target for delaying diabetic kidney disease progression, alongside other pathways, but does not provide specific efficacy data for AGEs alone.", "population_specificity": "Patients with diabetic nephropathy or at risk of end-stage renal disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.864153+00:00"}
{"study_id": 101922, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to determine whether modulating the receptor for advanced glycation end products (RAGE) could improve outcomes in sepsis by regulating immune responses.", "results_summary": "The study found inconsistent results regarding RAGE's role in sepsis, with some strategies (e.g., antibodies, genetic deletion) showing potential to regulate inflammation and endothelial function, but no clear consensus on its overall benefit.", "population_specificity": "Experimental models of sepsis (not human subjects).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:40.884718+00:00"}
{"study_id": 101926, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of the receptor for advanced glycation end products (RAGE) in eosinophil function and its involvement in immune responses, including allergic and malignant diseases.", "results_summary": "The study found that eosinophils express RAGE and other PRRs, which trigger immune responses such as cytokine release, oxidative burst, and cytotoxic protein release, suggesting their involvement in defense against pathogens and modulation of allergic and malignant diseases.", "population_specificity": "Human eosinophils (in vitro or ex vivo context, not explicitly stated).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:43.951468+00:00"}
{"study_id": 101927, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review recent data on the role of advanced glycation end products (AGEs) in the pathogenesis of calcinosis in connective-tissue diseases, particularly juvenile dermatomyositis (JDM) and systemic sclerosis.", "results_summary": "The study found that raised tissue expression of AGEs and their receptor is associated with calcinosis in systemic sclerosis and systemic lupus erythematosus. However, no standard therapy for calcinosis exists, though aggressive treatment of underlying inflammation may improve outcomes.", "population_specificity": "Patients with connective-tissue diseases, particularly juvenile dermatomyositis (JDM), systemic sclerosis, and systemic lupus erythematosus.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:49.095943+00:00"}
{"study_id": 101928, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) in diabetic nephropathy, particularly their interaction with TGF-\u03b2/Smad signaling pathways.", "results_summary": "The study found that AGEs, along with other profibrotic factors, activate Smad signaling pathways, contributing to renal fibrosis in diabetic nephropathy. Smad3 was identified as pathogenic, while Smad2 and Smad7 played protective roles, suggesting potential therapeutic targets.", "population_specificity": "The study focused on diabetic nephropathy, a complication of diabetes, but did not specify human or animal models in the abstract.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:50.538347+00:00"}
{"study_id": 101929, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) in diabetic retinopathy (DR) and explore their potential as a therapeutic target for reversing hyperglycemic memory.", "results_summary": "The study suggests that AGEs contribute to the \"metabolic memory\" phenomenon in DR, where vascular damage persists despite glycemic control, and highlights their potential as a target for molecular therapeutics to mitigate complications.", "population_specificity": "Working-age adults with type 1 and type 2 diabetes in developed nations.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:53.067403+00:00"}
{"study_id": 101931, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to explore potential therapeutic targets for chronic kidney disease (CKD), including advanced glycation end products (AGEs), and their role in disease progression.", "results_summary": "The abstract mentions that drugs targeting advanced glycation end products are at various stages of development but provides no specific results regarding their efficacy or effects on CKD progression.", "population_specificity": "Patients with chronic kidney disease (CKD), including those progressing to end-stage renal disease (ESRD).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:53.820934+00:00"}
{"study_id": 101930, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether circulating advanced glycation end products (AGEs), specifically plasma pentosidine, could predict future cardiovascular events in hemodialysis patients.", "results_summary": "The study found that patients in the high tertile for plasma pentosidine had a significantly higher risk for cardiovascular events (hazard risk: 1.74). The risk was more prominent in patients with low serum albumin levels, suggesting AGE levels could represent accumulated oxidative stress and help stratify cardiovascular risks in ESRD patients.", "population_specificity": "386 hemodialysis patients (243 male, 142 female) with renal insufficiency.", "effective_dosage": "Not specified", "study_duration": "Follow-up from December 2005 to March 2010 (approximately 4.25 years)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:54.237596+00:00"}
{"study_id": 101932, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to determine whether angiotensin II type 1 receptor blockers (ARBs), specifically olmesartan and telmisartan, could reduce plasma advanced glycation end product (AGE) levels in hypertensive patients on hemodialysis.", "results_summary": "Olmesartan significantly reduced systolic blood pressure and plasma pentosidine and CML levels after 24 weeks, while telmisartan showed no significant changes in AGE levels. Serum total free radical levels also tended to decrease with olmesartan.", "population_specificity": "Hypertensive patients on hemodialysis (n=24).", "effective_dosage": "Olmesartan (20 mg/day), telmisartan (40 mg/day), candesartan (8 mg/day).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:55.530681+00:00"}
{"study_id": 101933, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of RAGE and its ligands in the progression of diabetic angiopathy and explore potential therapeutic strategies targeting this axis.", "results_summary": "The study found that RAGE and its ligands are significant pathogenic triggers for vascular injuries in diabetes, with animal studies supporting this link. Targeting the RAGE-ligand axis may help alleviate diabetic vascular complications and reduce disease burden.", "population_specificity": "Patients with long-standing diabetes (micro- and macroangiopathy).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:36:57.037686+00:00"}
{"study_id": 101934, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to understand the roles of S100A8 and S100A9 in vascular cell types and their mechanisms of action, particularly through the receptor for advanced glycation end products, to explore new therapeutic strategies for cardiovascular diseases.", "results_summary": "The study found that S100A8/A9 proteins modulate inflammatory processes via Toll-like receptor 4 and the receptor for advanced glycation end products, with both pro-inflammatory and anti-inflammatory effects. Elevated plasma levels of S100A8/A9 predict cardiovascular events in humans, and their deletion partly protects mice from atherosclerosis.", "population_specificity": "Humans and Apoe(-/-) mice.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:00.467286+00:00"}
{"study_id": 101936, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review molecular factors, including Advanced Glycation End Products, that link obesity and osteoarthritis, focusing on their dysregulation and potential therapeutic implications.", "results_summary": "The abstract highlights that Advanced Glycation End Products are among the molecular players implicated in the intersection of adipose tissue and joint cell biology, with dysregulation in obesity and osteoarthritis, but does not specify their direct effects or outcomes.", "population_specificity": "Not specified (review of existing literature on obesity and osteoarthritis).", "effective_dosage": "Not available", "study_duration": "Not applicable (review study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:01.469722+00:00"}
{"study_id": 101938, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of S100P, particularly its interaction with the receptor for advanced glycation end products, in tumor growth, metastasis, and invasion.", "results_summary": "The study found that S100P, through its binding with the receptor for advanced glycation end products and other proteins, mediates tumor growth, metastasis, and invasion in multiple carcinomas, suggesting its potential as a diagnostic marker and therapeutic target.", "population_specificity": "Tumor cell lines and carcinomas (breast, pancreas, lung, ovary)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:02.079830+00:00"}
{"study_id": 101935, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 85, "study_goal": "The researchers aimed to determine whether Pyridoxamine dihydrochloride (Pyridorin) could provide renoprotective effects in patients with proteinuric type 2 diabetic nephropathy by inhibiting advanced glycation end products and scavenging reactive oxygen species.", "results_summary": "The study found no statistically significant effect of Pyridorin on serum creatinine levels overall, but suggested a potential benefit in patients with less renal impairment at baseline. The treatment effect appeared to differ by baseline renal function, with the lowest tertile of serum creatinine showing a modestly lower average change in serum creatinine.", "population_specificity": "317 patients with proteinuric type 2 diabetic nephropathy (mean age 63.9\u00b19.5 years, mean diabetes duration 17.6\u00b18.5 years).", "effective_dosage": "150 mg twice daily or 300 mg twice daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:03.467743+00:00"}
{"study_id": 101940, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) in activating the Smad pathway and their contribution to renal fibrosis and inflammation.", "results_summary": "The study found that AGEs can activate the Smad pathway via both TGF-\u03b2-dependent and independent mechanisms, contributing to renal fibrosis and inflammation, with Smad3 being pathogenic while Smad2 and Smad7 are protective.", "population_specificity": "Not specified (likely animal models, given the mention of gene knockout mice).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:04.362593+00:00"}
{"study_id": 101937, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) and their receptors (RAGE) in post-PCI restenosis and how statins might mitigate these effects.", "results_summary": "The study found that AGEs and RAGE contribute to post-PCI restenosis by promoting thrombogenesis, vascular smooth muscle cell proliferation, and extracellular matrix formation. Statins were shown to lower AGEs, decrease RAGE expression, and increase soluble RAGE (sRAGE), potentially reducing restenosis and myonecrosis.", "population_specificity": "Patients undergoing percutaneous coronary intervention (PCI).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:05.754736+00:00"}
{"study_id": 101939, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to determine whether type 2 diabetes and metabolic syndrome are associated with altered myocardial structure, microvasculature, and expression of AGEs and RAGE in men with coronary artery disease.", "results_summary": "The study found that impaired diastolic function in diabetic and metabolic syndrome patients was not linked to increased myocardial fibrosis, cardiomyocyte hypertrophy, altered microvascular structure, or elevated myocardial expression of AGEs or RAGE. These findings suggest that such changes may be a consequence rather than a cause of cardiac dysfunction.", "population_specificity": "Men with coronary artery disease undergoing coronary artery bypass graft surgery, including controls, diabetic patients, and metabolic syndrome patients.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:07.206184+00:00"}
{"study_id": 101941, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to understand the role of advanced glycation end products (AGEs) in age-related chondrocyte dysfunction and osteoarthritis progression.", "results_summary": "The study found that AGE accumulation contributes to chondrocyte senescence, impairing their response to mechanical and inflammatory insults, reducing anabolic activity, and increasing proinflammatory cytokine and matrix-degrading enzyme production, which may predispose articular cartilage to osteoarthritis.", "population_specificity": "Aging chondrocytes (not specified if human or animal model).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:08.122438+00:00"}
{"study_id": 101943, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the mechanisms linking oxidative stress to diabetic complications and explore therapeutic opportunities involving antioxidant properties, including those related to Advanced Glycation End Products (AGEs).", "results_summary": "The study found that oxidative stress, driven by factors like AGEs, contributes to diabetic complications, and intensive management of metabolic syndrome components reduced adverse cardiovascular outcomes.", "population_specificity": "Subjects with type 2 diabetes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:09.376224+00:00"}
{"study_id": 101942, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether differences in RAGE expression and its soluble form (sRAGE) underlie the differing clinical outcomes of hyperglycemia in diabetic and non-diabetic critically ill patients.", "results_summary": "The study found that sRAGE levels were higher in diabetic patients and decreased with intensive insulin therapy in this group but not in non-diabetic patients. sRAGE correlated with inflammatory markers but was not associated with mortality.", "population_specificity": "76 hyperglycemic critically ill patients (33 with type-2 diabetes, 43 without diabetes) aged \u226518 years.", "effective_dosage": "Not specified", "study_duration": "Measurements taken at ICU admission and on Days 1, 3, 5, and 7.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:09.777260+00:00"}
{"study_id": 101944, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to explore the association between advanced glycation end products and renal aging, alongside other clinical and tissue factors.", "results_summary": "The study found that advanced glycation end products are associated with renal aging, alongside factors like angiotensin II, oxidative stress, and Klotho. Possible interventions such as controlling blood pressure, blood sugar, and diet may help mitigate renal aging.", "population_specificity": "General aging population, particularly those with conditions like hypertension, diabetes, obesity, and abnormal lipid levels.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:11.068727+00:00"}
{"study_id": 101945, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 65, "study_goal": "The researchers aimed to review the effect of cigarette smoking on clinical outcomes after periodontal surgical interventions, particularly focusing on the role of advanced glycation end products in inflammation and wound healing.", "results_summary": "The study found that cigarette smoking negatively affects periodontal wound healing after surgical interventions, with compromised reductions in probing depth and gains in clinical attachment levels in smokers compared to nonsmokers. Residual recession was also significantly higher in smokers.", "population_specificity": "Smokers and nonsmokers undergoing periodontal surgical procedures.", "effective_dosage": "Not specified", "study_duration": "Smoking habit duration ranged from at least 5 years to 27.8 years.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:11.816812+00:00"}
{"study_id": 101946, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the formation, harmful effects, and potential inhibitors of Advanced Glycation End Products (AGEs) in relation to diseases like diabetes, atherosclerosis, and Alzheimer's.", "results_summary": "The study found that AGEs contribute to various diseases and aging, and highlighted natural products as promising inhibitors due to fewer side effects compared to synthetic compounds.", "population_specificity": "Not specified (general review of AGEs and their inhibitors)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:13.168266+00:00"}
{"study_id": 101947, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the role of advanced glycation end products (AGEs) in bone quality deterioration and fracture risk in type 2 diabetes mellitus (T2DM) patients.", "results_summary": "The study suggests that AGEs may contribute to bone fragility in T2DM by deteriorating bone quality rather than reducing bone mass, and identifies AGE-related markers as potential candidates for assessing fracture risk.", "population_specificity": "Elderly patients with type 2 diabetes mellitus (T2DM).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:14.912845+00:00"}
{"study_id": 101949, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the effects of insulin administration and Advanced Glycation End Products (AGEs) on mitochondrial function in hyperglycemic conditions, both in vivo and in vitro.", "results_summary": "The study found that hyperglycemia led to tissue-specific energy deficiencies, with cardiac tissue being most sensitive. Insulin therapy effectively protected against mitochondrial dysfunction, and AGE accumulation was linked to reduced mitochondrial function in fibroblasts.", "population_specificity": "Streptozotocin-induced hyperglycemic rats and human diabetic plasma samples.", "effective_dosage": "Not specified", "study_duration": "Short-term (10 days) and long-term (30 days) insulin administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:17.026604+00:00"}
{"study_id": 101950, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) and their receptor in mediating the bidirectional relationship between diabetes mellitus and periodontitis.", "results_summary": "The study found that AGEs and their receptor are expressed in the periodontium of individuals with diabetes and appear to mediate hyperinflammatory responses and impaired tissue repair, contributing to accelerated periodontal destruction. Periodontitis also adversely affects glycemic control in diabetes, and periodontal therapy can modestly improve glycemic control.", "population_specificity": "Individuals with diabetes mellitus (type 1 and type 2) and periodontitis.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:18.980843+00:00"}
{"study_id": 101952, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) in promoting renal damage, fibrosis, and inflammation in diabetic nephropathy, and explore potential pharmacological interventions to reduce AGEs.", "results_summary": "The study found that AGEs contribute to kidney damage, fibrosis, and inflammation in diabetic nephropathy by modifying protein structure/function and activating pathogenic mediators. Pharmacological agents targeting AGEs showed effectiveness in experimental models, but clinical utility remains unproven.", "population_specificity": "Diabetic individuals, particularly those with nephropathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:20.406739+00:00"}
{"study_id": 101951, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether dietary advanced glycation end products (AGEs) contribute to insulin resistance in type 2 diabetes and whether AGE restriction can improve insulin sensitivity by modulating AGER1 and SIRT1 pathways.", "results_summary": "The study found that an AGE-restricted diet reduced insulin resistance, inflammatory markers, and oxidative stress in type 2 diabetic patients while restoring AGER1 and SIRT1 levels. AGE restriction also improved adiponectin levels and suppressed pro-inflammatory pathways in vitro.", "population_specificity": "18 type 2 diabetic patients (age 61\u00b14 years) and 18 healthy subjects (age 67\u00b11.4 years).", "effective_dosage": "Standard diet (>20 AGE Eq/day) vs. AGE-restricted diet (<10 AGE Eq/day).", "study_duration": "4 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:20.991403+00:00"}
{"study_id": 101954, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to elucidate the molecular and cellular pathophysiologic mechanisms, structural changes, and therapeutic strategies related to diabetic cardiomyopathy, including the role of Advanced Glycation End Products.", "results_summary": "The abstract highlights that Advanced Glycation End Products contribute to increased stiffness in diabetic hearts by promoting fibrosis and connective tissue growth factor stimulation, but it does not provide specific efficacy or safety data.", "population_specificity": "Diabetic patients with or at risk of cardiomyopathy.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:22.441606+00:00"}
{"study_id": 101953, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to compare the effects of two peritoneal dialysis (PD) regimens (high vs. low glucose and GDP loads) on plasma levels of advanced glycation end products (AGEs) and related compounds.", "results_summary": "The low glucose/GDP regimen (NEPP) resulted in lower plasma levels of 3-DG and CEL compared to the standard PD regimen, but higher MGO levels and a steeper initial increase in CML. Both regimens showed significant changes in AGE-related markers after starting PD.", "population_specificity": "New continuous ambulatory peritoneal dialysis (PD) patients (n=50).", "effective_dosage": "Not specified (regimens involved 4 glucose-lactate exchanges for sPD vs. 1 amino acid, 1 icodextrin, and 2 glucose-bicarbonate/lactate exchanges for NEPP).", "study_duration": "Two 24-week periods (48 weeks total).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:24.976215+00:00"}
{"study_id": 101955, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine if aerobic exercise could reduce proinflammatory/-oxidative gene expression, including the receptor for advanced glycation end products (RAGE), in older adults.", "results_summary": "Older adults showed higher expression of proinflammatory/-oxidative genes, including RAGE, compared to younger adults. Aerobic exercise reduced or tended to reduce these gene expressions in older adults.", "population_specificity": "Healthy young (18-33 yr) and middle-aged/older (50-76 yr) adults.", "effective_dosage": "Brisk walking ~6 days/wk, 50 min/day, 70% of maximal heart rate.", "study_duration": "2 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:26.133348+00:00"}
{"study_id": 101956, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to investigate the role of Advanced Glycation End Products (AGEs) and their receptor RAGE in the pathogenesis of diabetic retinopathy, exploring potential therapeutic targets.", "results_summary": "The study found that AGEs accumulate in the retina due to chronic hyperglycemia, activating pro-oxidant and proinflammatory pathways via RAGE, contributing to sustained inflammation, neurodegeneration, and microvascular dysfunction in diabetic retinopathy. The AGE-RAGE axis presents potential therapeutic intervention points.", "population_specificity": "Diabetic patients, specifically those with or at risk for diabetic retinopathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:27.076301+00:00"}
{"study_id": 101948, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the effects of tocotrienols and tocopherols on reducing advanced glycation end products (AGEs) and other cardiovascular risk factors.", "results_summary": "Tocotrienols were found to reduce serum levels of advanced glycation end products (AGEs) and inflammatory markers more effectively than tocopherols, with \u03b4-tocotrienol being the most potent. Both compounds reduced AGEs, but tocotrienols showed broader cardiovascular benefits, including antithrombotic and anti-atherosclerotic effects.", "population_specificity": "Experimental animals and potential human applications (e.g., patients undergoing angioplasty, stent implantation, or bypass surgery).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:27.923227+00:00"}
{"study_id": 101957, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) and their interaction with HMGB1, TLR, and RAGE in the inflammatory pathways associated with diabetes.", "results_summary": "The study found that AGEs, through interactions with HMGB1-TLR-RAGE, contribute to chronic inflammation in diabetes by activating NF-\u03baB and increasing pro-inflammatory cytokines. Blocking HMGB1 or modulating this pathway may offer a therapeutic approach for diabetes.", "population_specificity": "Not specified (theoretical/mechanistic focus).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:27.977824+00:00"}
{"study_id": 101958, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to systematically review the association between skin autofluorescence (SAF), measured by the AGE Reader, and complications of diabetes.", "results_summary": "All seven studies reviewed showed positive associations of SAF with diabetes complications (e.g., mortality, cardiovascular issues, neuropathy, nephropathy), except retinopathy. However, studies had large clinical heterogeneity, and only three were prospective.", "population_specificity": "Patients with diabetes mellitus type 1 and type 2.", "effective_dosage": "Not mentioned", "study_duration": "Follow-up ranged from 3-5 years in prospective studies; others were cross-sectional.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:28.573463+00:00"}
{"study_id": 101959, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of metformin or pioglitazone on serum pentosidine levels (a marker of AGEs) in type 2 diabetes patients.", "results_summary": "Both metformin and pioglitazone significantly reduced serum pentosidine levels after 6 months, with greater percent changes compared to the control group, suggesting these agents may help prevent diabetic complications linked to AGEs accumulation.", "population_specificity": "66 Japanese patients with type 2 diabetes.", "effective_dosage": "Clinical doses (specific amounts not stated).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:30.343253+00:00"}
{"study_id": 101960, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the role of the AGE-oxidative stress axis and its therapeutic interventions in vascular complications in diabetes.", "results_summary": "The study found that AGEs contribute to oxidative stress, inflammation, and thrombogenic reactions via RAGE interaction, exacerbating vascular complications in diabetes. It also identified a crosstalk between the AGE-RAGE axis and RAS, suggesting potential therapeutic targets.", "population_specificity": "Individuals with diabetes (specific population not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:33.322649+00:00"}
{"study_id": 101961, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the role of the RAGE-ligand axis in liver diseases, including fibrosis, inflammation, and regeneration, and highlight open issues for future research.", "results_summary": "The study found that the RAGE-ligand axis contributes to liver fibrosis, inflammation, and regeneration, with soluble RAGE acting as a decoy to neutralize circulating ligands. The axis's role in liver diseases remains unclear despite established involvement in other conditions like diabetes and neurodegeneration.", "population_specificity": "Not specified (literature review covering experimental and clinical studies).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:34.190218+00:00"}
{"study_id": 101963, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to explore potential mechanisms linking diabetes mellitus (DM) and Alzheimer disease (AD), focusing on brain insulin signaling and cerebrovascular alterations involving advanced glycation end products (RAGE).", "results_summary": "The study suggests that DM may contribute to AD progression through mechanisms like altered brain insulin signaling and cerebrovascular dysfunction, rather than solely through beta-amyloid peptide modulation. Interactions between RAGE and A\u03b2 peptides may play a role in cerebrovascular dysfunction in AD.", "population_specificity": "Mouse models showing pathological manifestations of both DM and AD.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:36.083441+00:00"}
{"study_id": 101964, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to explore potential mechanisms linking diabetes (particularly type 2) to increased cancer risk, including the role of Advanced Glycation End Products.", "results_summary": "The abstract suggests Advanced Glycation End Products may contribute to increased cancer risk in diabetics, but the evidence is inconclusive. No direct efficacy or safety data on Advanced Glycation End Products are provided.", "population_specificity": "Diabetic patients, particularly those with type 2 diabetes.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:36.378702+00:00"}
{"study_id": 101962, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine if azelnidipine could reduce renal injury in hypertensive CKD patients by inhibiting the AGE-RAGE axis.", "results_summary": "Azelnidipine, but not amlodipine, reduced circulating AGE, sRAGE, proteinuria, and tubular injury markers independently of blood pressure effects. Both drugs lowered blood pressure comparably but did not affect glucose, HbA1c, lipids, or eGFR.", "population_specificity": "Nondiabetic stage I or II CKD patients already treated with angiotensin II receptor blockers.", "effective_dosage": "16 mg azelnidipine or 5 mg amlodipine once daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:36.871142+00:00"}
{"study_id": 101965, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of non-surgical periodontal therapy on inflammatory biomarkers, including soluble receptor of advanced glycation end products (sRAGE), in poorly controlled type 2 diabetes mellitus (T2DM) patients with periodontal disease.", "results_summary": "The study found small changes in plasma sRAGE levels after non-surgical periodontal therapy, but these changes were not significant. The therapy improved periodontal health and moderately reduced HbA1c levels but did not significantly affect sRAGE, IL-6, or CRP levels.", "population_specificity": "Poorly controlled type 2 diabetes mellitus (T2DM) patients with periodontal disease (n=28).", "effective_dosage": "Not specified for sRAGE; subgingival minocycline was used in one group (dosage not detailed).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:38.864395+00:00"}
{"study_id": 101966, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if reducing advanced glycation end-products (AGEs) through dietary and pharmaceutical interventions could improve obesity-related renal dysfunction.", "results_summary": "A low-AGE diet improved renal function and inflammatory markers in overweight/obese individuals. In mice, AGE-lowering treatment (alagebrium) and RAGE deletion improved renal function, inflammation, and oxidative stress, while also reducing weight gain and improving glycemic control.", "population_specificity": "Overweight and obese individuals (BMI 26-39 kg/m\u00b2) and a mouse model of obesity.", "effective_dosage": "Not specified", "study_duration": "2 weeks (human trial); duration in mice not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:38.930907+00:00"}
{"study_id": 101967, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether irbesartan treatment affects plasma levels of AGEs (CML and CEL) in hypertensive patients with type 2 diabetes and microalbuminuria.", "results_summary": "The study found no significant changes in CML and CEL levels over time in either the irbesartan or placebo group, indicating no effect of irbesartan on these AGEs. Mean differences between groups were negligible and not statistically significant.", "population_specificity": "Hypertensive patients with type 2 diabetes and microalbuminuria.", "effective_dosage": "300 mg irbesartan daily.", "study_duration": "2 years.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:41.454322+00:00"}
{"study_id": 101968, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the role of glyoxalase 1 in psychiatric disorders and its impact on dicarbonyl glycation and advanced glycation end products.", "results_summary": "The study found inconsistent associations between glyoxalase 1 expression and anxiety-related behavior in mice, suggesting that dicarbonyl substrate concentration may play a more significant role in psychiatric disorders than previously thought.", "population_specificity": "Clinical studies (humans with major depression, panic disorders, schizophrenia) and mouse models (trait anxiety).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:42.112249+00:00"}
{"study_id": 101971, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to compare the effects of sevelamer and calcium carbonate on coronary artery calcification and advanced glycation end products (AGEs) in hemodialysis patients.", "results_summary": "Sevelamer slowed the progression of coronary artery calcification and suppressed AGE accumulation compared to calcium carbonate, with a significantly lower increase in calcification scores and pentosidine levels.", "population_specificity": "183 adult hemodialysis patients with a mean vintage of 118 \u00b1 89 months.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:44.144019+00:00"}
{"study_id": 101972, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to review current treatments and therapeutic strategies, including those targeting advanced glycation end products, for Alzheimer's disease.", "results_summary": "The abstract mentions that modulating advanced glycation end products is an emerging therapeutic strategy, but no specific results regarding its effects are provided.", "population_specificity": "Patients with Alzheimer's disease (general mention, no specific subgroup details).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:44.819198+00:00"}
{"study_id": 101970, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the role of Advanced Glycation End Products (AGEs) as a pathophysiological factor linking heart and renal failure, and their potential as a treatment target in heart failure patients.", "results_summary": "The study found that AGE accumulation is associated with diastolic dysfunction and renal failure, particularly in elderly, diabetic, and renal failure patients, suggesting a role in the development and progression of these conditions. The abstract also hints at AGE intervention as a possible treatment strategy for heart failure.", "population_specificity": "Elderly patients, diabetic patients, and patients with renal failure.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:44.944032+00:00"}
{"study_id": 101969, "supplement_id": 857, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of lycopene on soluble receptor for advanced glycation end products (sRAGE) levels in blood and seminal plasma in normospermic males.", "results_summary": "Lycopene administration significantly decreased sRAGE levels in seminal plasma in both fertile volunteers and normospermic male partners from infertile relationships, but had no significant effect on sRAGE in blood plasma. The findings suggest selective local uptake of lycopene in the male reproductive tract, potentially suppressing oxidative stressors.", "population_specificity": "15 fertile volunteers and 13 normospermic male partners from infertile relationships.", "effective_dosage": "20 mg of lycopene daily.", "study_duration": "12 weeks per treatment phase, with a crossover design for a total of 24 weeks.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T19:37:45.125948+00:00"}
